

ECTOPIC EXPRESSION OF *mnb* AND *Hip1* ALTERS
DROSOPHILA DEVELOPMENT

JILLIAN M. MacDONALD

Ectopic expression of *mnb* and *Hip1* alters *Drosophila* development

by

Jillian M. MacDonald

A thesis submitted to the

School of Graduate Studies

in partial fulfillment of the

requirements for the degree of

Master of Science

Department of Biology

Memorial University of Newfoundland

August 2008

St. John's

Newfoundland and Labrador

Abstract

A powerful approach to studying the mechanisms of disease is through the use of transgenic models like *Drosophila melanogaster*. The *Drosophila* homologue of the human Down syndrome candidate gene, *Dyrk1A*, is *minibrain* (*mnb*). Studies have shown that *mnb* can participate in development of the *Drosophila* eye to control growth and survival through modification of insulin receptor signalling. Huntingtin-interacting protein 1 (Hip1), which differentially interacts with the mutant and normal forms of the Huntington disease protein, huntingtin, has been shown to play a role in *Drosophila* neurogenesis. There are two naturally occurring versions of the Hip1 protein, a full length version and a truncated version missing the N-terminal ANTH domain, referred to as Hip1 Δ ANTH. As a biochemical interaction has been identified between *Hip1* and *Dyrk1A/mnb*, this study examines these two genes in *Drosophila* development. In this study the *UAS-Gal4* system was utilized to direct the expression of *Dyrk1A/mnb*, *Hip1* and components of the insulin signalling pathway, *akt* and *foxo1*, in the developing dorsal notum and eye. While neither *mnb* nor *foxo1* over-expression has any effect, we found that over-expression of *akt*, a component of the insulin signalling pathway, increases the microchaetae density on the dorsal notum. The over-expression of *mnb* and *Hip1* in the eye have no effect on eye development. Under the sensitized growth conditions where the *GMRGal4* also drives the *UASfoxo11* transgene, the full length versions of *Hip1* show decreased bristle number and decreased ommatidia number while the truncated versions of *Hip1* lacking the lipid-binding ANTH domain show decreased ommatidia number. Over-expression of *mnb* and *Hip1* together with *foxo1* show changes in eye development, indicating a possible interaction between these two genes. As these are genes in two completely different diseases, finding how they interact could provide a key insight into finding therapies for neurodegenerative diseases.

Acknowledgements

I would like to express my gratitude to my supervisor, Dr. Brian Staveley for his support and guidance through this project and for exceeding his duties as a supervisor to help prepare this thesis in a very short time period.

I would like to thank the members of the Staveley lab, both past and present. In particular, I would like to thank Jen, my work-out buddy for keeping me sane and helping with editing. Thanks to Mike for being there from day one. A big thank you to Amy who always manages to fix everything and Jo-Anna for always providing comic relief. Finally, thanks to Shawn Hussey, Colleen Connors and Stephanie Mooney for help with analysis.

Thank you to Lisa Lee, Liqui Men, and Michael Shaffer for help with SEM imaging, and to Gary Collins and Peter Woodman for technical help.

I would like to thank the members of my committee, Dr. Helene Volkoff and Dr. Dawn Marshall for their helpful suggestions.

Lastly, I would like to thank Dylan Reid for his love, support and constant patience throughout this project. I could never have done it without you!

Table of Contents

Abstract	ii
Acknowledgements	iii
List of Tables	vii
List of Figures	viii
List of Abbreviations	x
Introduction	1
<i>Drosophila</i> as a model organism.....	1
The UAS-Gal4 system in <i>Drosophila</i>	1
<i>Drosophila</i> eye growth and differentiation.....	2
The <i>Drosophila notum</i> as a model of neurogenesis	3
Down syndrome: Characteristics of the disease	4
Down syndrome: Genetic causes	4
Identification and nomenclature of <i>Dyrk1A/mnb</i>	5
<i>Dyrk1A/mnb</i> interacts with a large number of proteins	6
<i>Dyrk1A/mnb</i> studies in vertebrates	7
<i>Dyrk1A/mnb</i> studies in non-invertebrates	8
<i>mnb</i> studies in <i>Drosophila</i>	9
Huntington disease: Characteristics of the disease	10
Huntington disease: Genetic causes.....	11
Identification and studies of huntingtin.....	12
Studies of huntingtin in <i>Drosophila</i>	13
Huntingtin-interacting proteins.....	13
<i>Hip1</i> characterization.....	15
<i>Hip1</i> functions in cell death, cell growth and endocytosis.....	16
Study of <i>Hip1</i> in <i>Drosophila</i>	17

A link between <i>Hip1</i> and <i>Dyrk1A/mnb</i>	18
Goals of this research.....	19
Materials and Methods	20
Investigating the role of <i>mnb</i> , <i>akt</i> , and <i>foxo1</i> in neurogenesis.....	20
<i>Drosophila</i> stocks.....	20
<i>Drosophila</i> culture.....	22
Biometric analysis of dorsal notum microchaetae.....	25
The potential role of <i>Huntingtin interacting protein-1</i> and <i>minibrain</i> in eye development using <i>GMRGal4</i>	26
<i>Drosophila</i> stocks.....	26
<i>Drosophila</i> culture.....	28
Biometric analysis of the adult eye.....	30
Interaction of <i>foxo1</i> with <i>mnb</i> and <i>Hip1</i>	31
<i>Drosophila</i> stocks, culture and analysis.....	31
Interaction of <i>mnb</i> and <i>Hip1</i> with each other.....	33
<i>Drosophila</i> stocks.....	33
Generation of <i>mnb</i> ; <i>Hip1</i> lines.....	33
For <i>Hip1</i> on the third chromosome.....	33
For <i>Hip1</i> on the second chromosome.....	36
<i>Drosophila</i> culture and analysis.....	39
Results	41
Investigation of neurogenesis in the dorsal notum.....	41
<i>mnb</i> has no effect on neurogenesis in the dorsal notum.....	41
<i>akt</i> over-expression affects neurogenesis in the dorsal notum but <i>foxo1</i> over-expression does not.....	46
The potential role of <i>Huntingtin interacting protein-1</i> and <i>mnb</i> in eye development using <i>GMRGal4</i>	56

<i>Hip1</i> has no effect on eye development under standard growth conditions.....	56
<i>mnb</i> affects eye development.....	63
Interaction of <i>foxo1</i> with <i>mnb</i> and <i>Hip1</i>	67
<i>Hip1</i> and <i>Hip1</i> Δ <i>ANTH</i> differentially affect eye development under conditions of <i>foxo1</i> -sensitized eye development.....	67
Interaction of <i>mnb</i> and <i>Hip1</i> with each other.....	77
The interaction between <i>mnb</i> and <i>Hip1</i> alters <i>foxo1</i> -sensitized eye development when compared to <i>mnb</i> with <i>foxo1</i> and <i>Hip1</i> with <i>foxo1</i>	77
Discussion.....	89
References.....	96
Appendix 1.....	106

List of Tables

Table 1. The genotypes of stocks used to study the potential role of <i>mnb akt</i> , and <i>foxo1</i> in neurogenesis, their sources, and abbreviations used throughout the thesis.....	21
Table 2. The genotypes of stocks used to study the potential role of <i>Hip1</i> , <i>Hip1ΔANTH</i> and <i>mnb</i> in eye development, their sources, and abbreviations used throughout the thesis.....	27
Table 3. Comparison of microchaetae density changes in the dorsal notum in response to <i>mnb</i> , <i>akt</i> , and <i>foxo1</i> over-expression.....	55
Table 4. Comparison of differences in ommatidia area, bristle number and ommatidia number when <i>mnb</i> or <i>Hip1/Hip1ΔANTH</i> is expressed along with <i>foxo1</i> via the <i>GMRGal4</i> transgene....	75
Table 5. Comparison of differences in ommatidia area, bristle number and ommatidia number when <i>mnb</i> and/or <i>Hip1/Hip1ΔANTH</i> is expressed along with <i>foxo1</i> via the <i>GMRGal4</i> transgene.....	87

List of Figures

Figure 1. Schematic diagram of crosses made to examine the potential effects of <i>mnb</i> , <i>akt</i> , and <i>foxo1</i> on neurogenesis using the <i>apterousGal4</i> transgene.....	23
Figure 2. Schematic diagram of crosses made to examine the potential effects of <i>mnb</i> , <i>akt</i> , and <i>foxo1</i> on neurogenesis using the <i>pannierGal4</i> transgene.....	24
Figure 3. Schematic diagram of crosses made to examine the potential effects of <i>Hip1</i> , <i>Hip1ΔANTH</i> and <i>mnb</i> in eye development using the <i>GMRGal4</i> transgene	29
Figure 4. Schematic diagram of crosses made to look at the potential effects of <i>Hip1</i> , <i>Hip1ΔANTH</i> and <i>mnb</i> in eye development with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes.....	32
Figure 5. Schematic diagram of crosses made to establish <i>UASmnb</i> ; <i>Ly/TM6B</i> stocks to examine the potential interaction of <i>Hip1</i> and <i>Hip1ΔANTH</i> with <i>mnb</i> in eye development with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes.....	34
Figure 6. Schematic diagram of crosses made to establish <i>UASmnb</i> ; <i>UASHip1</i> combination stock lines for <i>Hip1</i> on the third chromosome that will be used to examine the potential interaction of <i>Hip1</i> and <i>Hip1ΔANTH</i> with <i>mnb</i> in eye development with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes.....	35
Figure 7. Schematic diagram of crosses made to establish <i>UASmnb</i> ; <i>L/CyO</i> ; <i>+ / TM3</i> , <i>Sb</i> stocks to examine the potential interaction of <i>Hip1</i> and <i>Hip1ΔANTH</i> with <i>mnb</i> in eye development with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes.....	37
Figure 8. Schematic diagram of crosses made to establish <i>UASmnb</i> ; <i>UASHip1</i> combination stock lines for <i>Hip1</i> on the second chromosome that will be used to examine the potential interaction of <i>Hip1</i> and <i>Hip1ΔANTH</i> with <i>mnb</i> in eye development with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes.....	38
Figure 9. Schematic diagram of crosses made to examine the potential effects of <i>Hip1</i> and <i>Hip1ΔANTH</i> with <i>mnb</i> in eye development with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes.....	40
Figure 10. Biometric analysis of a potential role of <i>mnb</i> in neurogenesis with the <i>apterousGal4</i> transgene in females.....	42
Figure 11. Biometric analysis of a potential role of <i>mnb</i> in neurogenesis with the <i>pannierGal4</i> transgene in females.....	44
Figure 12. Biometric analysis of a potential role of <i>akt</i> in neurogenesis with the <i>apterousGal4</i> transgene in females.....	47
Figure 13. Biometric analysis of a potential role of <i>akt</i> in neurogenesis with the <i>apterousGal4</i> transgene in males.....	49

Figure 14. Biometric analysis of a potential role of <i>akt</i> and <i>foxo1</i> on neurogenesis with the <i>pannierGal4</i> transgene in females.....	51
Figure 15. Biometric analysis of a potential role of <i>akt</i> and <i>foxo1</i> in neurogenesis with the <i>pannierGal4</i> transgene in males.....	53
Figure 16. Biometric analysis of a potential role of <i>Hip1</i> and <i>Hip1ΔANTH</i> on eye development using the <i>GMRGal4</i> transgene in females.....	57
Figure 17. Biometric analysis of a potential role of <i>Hip1</i> and <i>Hip1ΔANTH</i> on eye development using the <i>GMRGal4</i> transgene in males.....	60
Figure 18. Biometric analysis of a potential role of <i>mnb</i> in eye development using the <i>GMRGal4</i> transgene in females.....	64
Figure 19. Biometric analysis of a potential role of <i>Hip1</i> , <i>Hip1ΔANTH</i> and <i>mnb</i> in eye development using the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes in females.....	69
Figure 20. Biometric analysis of a potential role of <i>Hip1</i> , <i>Hip1ΔANTH</i> and <i>mnb</i> on eye development using the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes in males.....	72
Figure 21. Biometric analysis of the interaction between <i>mnb</i> and <i>Hip1</i> during eye development along with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes in females.....	79
Figure 22. Biometric analysis of the interaction between <i>mnb</i> and <i>Hip1</i> during eye development along with the <i>GMRGal4</i> and <i>UASfoxo1</i> transgenes in males.....	83

List of Abbreviations

A	adenine
ANOVA	analysis of variance
ANTH	AP-180 N-terminal homology
AP2	adapter protein 2
Arip4	androgen receptor-interacting protein 4
bFGF	basic fibroblast growth factor
C	cytosine
cAMP	cyclic adenosine monophosphate
cDNA	complementary deoxyribonucleic acid
CRE	cAMP response element
CREB	cAMP response element binding
C-terminal	carboxy-terminal
DNA	deoxyribonucleic acid
DRPLA	dentatorubral pallidoluysian atrophy
DS	Down syndrome
DCR-1	Down syndrome critical region
Dyrk1A	dual specificity tyrosine phosphorylation-regulated kinase dual-specificity YAK1-related kinase A
eIF2Bε	eukaryotic initiation factor 2Bepsilon
ENTH	epsin N-terminal homology
ESEM	environmental scanning electron microscope
foxo1	forkhead homeobox type O
G	guanine
GABA	gamma-aminobutyric acid
GAPDH	glyceraldehyde-3-phosphate dehydrogenase

GFP	green fluorescent protein
GMR	glass multiple reporter
HD	Huntington disease
Hap1	Huntingtin-associated protein
Hip1	Huntingtin-interacting protein 1
Hip2	Huntingtin-interacting protein 2
htt	huntingtin
KDa	kiloDalton
mnb	minibrain
mRNA	messenger ribonucleic acid
N-terminal	amino terminal
NFAT	nuclear factor of activated T cells
PAHX-AP1	phytanoyl-CoA α -hydroxylase associated protein 1
PCR	polymerase chain reaction
pDED	pseudo-death effector domain
polyQ	polyglutamine
PtdIns(4,5)P ₂	phosphatidylinositol 4,5-bisphosphate
Q	glutamine
SEM	standard error of the mean
SF3b1	splicing factor 3b, subunit 1
Sla2p	synthetic lethal with actin binding protein (ABP) 1
STAT3	signal transducer and activator of transcription 3
UAS	upstream activating sequence
YAC	yeast artificial chromosome
X	times

Introduction

Drosophila as a model organism

A powerful approach to the study of mechanisms of disease is through the use of transgenic models. Notably, *Drosophila melanogaster* has many attributes that make it a valuable research tool, such as a rapid life cycle, large numbers of offspring and ease of maintenance, that make it ideal for genetic experimentation (Bier 2005). Approximately 75% of known human disease genes have homologues in *Drosophila* (Bier 2005), which makes it possible to characterize the biological properties associated with the *Drosophila* homologues. Furthermore, many developmental processes have been conserved throughout evolutionary history, so study in *Drosophila* can provide insights into the mechanisms of similar processes in humans (Bier 2005). Specifically, *Drosophila* has been used to study developmental disorders, neurological diseases such as Alzheimer, Parkinson and Huntington disease, trinucleotide repeat disorders (such as dentatorubral pallidoluysian atrophy), and cancer (reviewed in Bier 2005; Sang and Jackson 2005). Given the diversity of studies that have utilized *Drosophila*, it is an excellent choice as a model organism in which to study homologues of disease genes.

The UAS-Gal4 system in Drosophila

The UAS-Gal4 system, a directed or ectopic expression system used to express genes, is one of many molecular and genetic techniques available to manipulate *Drosophila* (Phelps and Brand 1998). This system utilizes the yeast transcription factor gene, *Gal4*, and its protein target sequence UAS (upstream activating sequence) to drive

the expression of genes in specific cells and tissues at precise times throughout the life of the organism. These two genes are maintained in separate transgenic fly lines. When crossed, the target gene is activated in the progeny due to the Gal4 protein binding to the *UAS* element in the enhancer region of the target gene to induce transcription (Phelps and Brand 1998). The *UAS-Gal4* system will be utilized in this study to direct the expression of *Dyrk1A/mnb*, the Down syndrome candidate gene, *Huntingtin-Interacting Protein 1* and genes of the insulin receptor-signaling pathway, *akt* and *foxo1*.

Drosophila eye growth and differentiation

The *Drosophila* eye normally contains a hexagonal pattern of 750-800 ommatidia (light-sensing units) that is the product of a series of precise events that take place during development (reviewed in Bonini and Fortini 1999; Thomas and Wassarman 1999; Baker 2001; Frankfort and Mardon 2002). Differentiation of the cells that comprise the adult eye begins in the mid-third instar in the eye imaginal disc. The morphogenetic furrow moves from posterior to anterior across the eye disc as progressively more anterior disk regions begin eye differentiation. Each ommatidia contain eight photosensitive neurons, or photoreceptors, for a total of over 6000 neurons in the eye. In addition, accessory cells, including four lens-secreting cone cells, two primary pigment cells, shared secondary and tertiary pigments cells, and a four-cell mechanosensory bristle organ comprise each ommatidia (reviewed in Bonini and Fortini 1999; Thomas and Wassarman 1999; Baker 2001; Frankfort and Mardon 2002). As the mechanism of *Drosophila* eye development is highly reproducible and consistent, the eye is a very useful tool for the study of subtle abnormalities such as subtle defects in a single

cell type or fraction of cells of a certain type. Moreover, in the laboratory, the phenotype of the eye does not influence viability and fertility.

Approximately two thirds of the 13,600 genes in *Drosophila* are required for eye development, with the vast majority of these being required for general cellular processes (Sang and Jackson 2005). The study of the *Drosophila* eye has proven to be a powerful means to investigate gene function and is used to study cell growth and differentiation, programmed cell death, and tissue patterning (Kramer and Staveley 2003; Kramer *et al.* 2003; reviewed in Thomas and Wassarman 1999; Frankfort and Mardon 2002; Sang and Jackson 2005). Given its ability to show subtle, yet significant results, the *Drosophila* eye is an important tool for studying the effects of gene expression.

The *Drosophila* notum as a model of neurogenesis

Microchaetae development on the dorsal notum of flies is a measure of neurogenesis, as bristles are mechanosensory organs formed from proneural cells (Jan and Jan 1994). For the most part, the dorsal notum is a two dimensional sheet of sensory bristles called microchaetae, or small bristles, and macrochaetae, or larger bristles. In the first stages of neural development, the proneural genes are turned on in the proneural clusters, giving those cells the potential to become neural precursors. Within those proneural clusters, the cells compete with each other through the actions of neurogenic genes, including *Notch*, *Delta* and the *enhancer of split* gene complex, so that only a subset of the cells give rise to neural precursors. These neural precursors will eventually give rise to the mechanosensory bristle organs. Therefore, the number of sensory bristles formed on the dorsal notum can be correlated to the number of sensory neurons (Jan and

Jan 1994). Although not as widely used as the eye, the dorsal notum has been used to study the *Notch* signaling pathway genes (Romain *et al.* 2001) as well as the effects of *Hip1* gene expression on neurogenesis (Moores *et al.* 2008). With its regular pattern of macrochaetae and microchaetae, the *Drosophila* dorsal notum is a reliable means to study neurogenesis.

Down syndrome: Characteristics of the disease

Down syndrome (DS) is a neurogenerative disorder affecting one in 700 live births and is the most frequent cause of mental retardation in humans (Jacobs *et al.* 1959; Coyle *et al.* 1986). Individuals with DS typically have a reduction in brain size and brain weight, reduction of neurons in the cerebellum and the hippocampus, reduction of the cholinergic neurons of the basal forebrain and the granular layers of the cerebral cortex, and several abnormal neuronal differentiation processes (Guimerá *et al.* 1996). In addition to neuronal defects, DS patients have congenital heart abnormalities, seizure disorders, low muscle tone, gastrointestinal malformations, defects of the endocrine and immune system, increased rate of leukemia and early onset Alzheimer disease (Coyle *et al.* 1986; Korenberg *et al.* 1994). Given the prevalence and severity of this condition, the genetic and molecular causes of this condition must be fully understood.

Down syndrome: Genetic causes

DS is the result of a total or partial triplication of human chromosome 21. Studies of rare cases of partial trisomy of chromosome 21 have resulted in the identification of a small section of this chromosome, 21q22.2, known as the “Down syndrome critical

region” (DCR-1), which is responsible for the phenotypes commonly observed in DS patients (Delabar *et al.* 1993; Antonarakis 2001). One of the best studied candidate genes located in DCR-1 is the “dual specificity tyrosine phosphorylation-regulated kinase”, or “dual-specificity YAK1-related kinase A”, *Dyrk1A*, and this gene has been investigated in brain function and development (Guimerá *et al.* 1996). Studies of the role of *Dyrk1A* is a promising avenue of research to understand the mechanisms underlying Down syndrome.

Identification and nomenclature of *Dyrk1A/mnb*

The acronym “Dyrk1A” refers to the ability of this family of kinases to phosphorylate serine/threonine and tyrosine residues and to sequence similarity with the protein kinase YAK1 from *Saccharomyces cerevisiae* (Becker and Joost 1999). In addition to the kinase domain, *Dyrk1A* contains a stretch of histidine repeats and a nuclear localization signal (Becker and Joost 1999). The first vertebrate Dyrk1A was identified in rodent models using a polymerase chain reaction (PCR) cloning method specific to the protein kinases (Kentrup *et al.* 1996). The human version of the gene was discovered by screening a human cDNA library with a putative exon isolated using an exon-trapping method, and verified to be a *Dyrk1A* gene based upon sequence similarities with the rat and *Drosophila* versions (Shindoh *et al.* 1996). The highly conserved nature of *Dyrk1A* suggests the importance of this gene in normal development.

The *Drosophila* homologue of the human *Dyrk1A* is *minibrain (mnb)*, the first member of the Dyrk family discovered. The *mnb* gene was identified in *Drosophila* through analysis of the *mnb* mutations, named due to the phenotypic “smaller brain” in

adult *mnb* mutants and was characterized by positional cloning (Tejedor *et al.* 1995). The human and *Drosophila* versions of the *mnb* protein exhibit a 75% amino acid sequence similarity (Shindoh *et al.* 1996). Although *mnb* was first described over a decade ago, very little research has been described in *Drosophila* since then.

***Dyrk1A/mnb* interacts with a large number of proteins**

Phosphorylation is an important mechanism of signal transduction in eukaryotic cells (Becker and Joost 1999). *Dyrk1A/mnb*'s ability to catalyze tyrosine-directed autophosphorylation and proline-directed phosphorylation of serine/threonine residues on exogenous substrates allows it to act with a high degree of versatility and substrate specificity. *Dyrk1A/mnb* has been shown to phosphorylate substrates in the nucleus such as STAT3 (signal transducer and activator of transcription 3) (Matsuo *et al.* 2001), cyclin L2 proteins (de Graaf *et al.* 2004), chromatin remodeling factors, SNR1 and TRX (Kinstrie *et al.* 2006), and the splicing factor SF3b1/SAP155 (de Graaf *et al.* 2006). In addition, the transcription factor Arip4 (androgen receptor-interacting protein 4) (Sitz *et al.* 2004) and the eukaryotic protein-synthesis initiation factor eIF2Bε (eukaryotic initiation factor 2Bε) (Woods *et al.* 2001a) are phosphorylated by *Dyrk1A/mnb*. *Dyrk1A/mnb* induces cAMP response element (CRE) mediated gene transcription by activating c-AMP response element binding protein (CREB) (Yang *et al.* 2001), Gli1 (Mao *et al.* 2002), the forkhead transcription factor, foxo1 (Woods *et al.* 2001b), and the NFAT (nuclear factor of activated T cells) family of transcription factors (Gwack *et al.* 2006), suggesting a role for *Dyrk1A/mnb* in gene expression. Proteins in the cytoplasm including 14-3-3 (Kim *et al.* 2004), glycogen synthase (Skurat and Dietrich 2004),

dynamamin (Chen-Hwang *et al.* 2002), and the brain specific protein, PAHX-AP1 (phytanoyl-CoA α -hydroxylase associated protein 1) are also phosphorylated by Dyrk1A/mnb (Bescond and Rahmani 2005). Dyrk1A/mnb also interacts with tau, a microtubule-associated protein (Woods *et al.* 2001a). This broad range of interactions suggests that *Dyrk1A/mnb* may be involved in numerous signaling pathways *in vivo*.

***Dyrk1A/mnb* studies in vertebrates**

An extra copy of *Dyrk1A/mnb* is hypothesized to play a major role in the developmental anomalies associated with DS (Wegiel *et al.* 2004). *Dyrk1A/mnb* is expressed in regions of the embryonic and adult rat brain that include the cerebellum, cerebral cortex, hippocampus and brain stem, as well as the heart (Okui *et al.* 1999; Marti *et al.* 2003). Northern blot analysis with mRNA from human and mouse fetal brain tissue revealed that *Dyrk1A/mnb* is over-expressed in the fetal DS human brain as well as in a mouse model of DS (Guimera *et al.* 1999). In the developing and adult human brain, Dyrk1A/mnb was found in the nucleus and cytoplasm of neurons (Wegiel *et al.* 2004). The presence of *Dyrk1A/mnb* in the nucleus suggests that it may play a role in the control of gene expression. In mouse brain development, the first wave of *Dyrk1A/mnb* expression participates in the transition of neural progenitor cells from proliferating to neurogenic divisions. This suggests that *Dyrk1A/mnb* plays a role in the neurogenesis of the vertebrate brain (Hämmerle *et al.* 2002). A second wave of *Dyrk1A/mnb* expression occurs in intermediate and late stage embryos during dendritic tree differentiation. In these stages, *Dyrk1A/mnb* expression is initiated by the translocation from the cytoplasm to the nucleus and then movement to the growing dendritic tree where the Dyrk1A/mnb

protein colocalizes with dynamin 1, a key protein in receptor-mediated endocytosis (Hämmerle *et al.* 2003). Murine models of DS that over-express *Dyrk1A/mnb* display motor, learning and memory deficits in behavioural studies that seem to recapitulate the cognitive defects observed in DS (Smith *et al.* 1997; Branchi *et al.* 2004; Martínez de Lagrán *et al.* 2004). Transgenic mice that contain only one copy of the *Dyrk1A/mnb* gene show significant impairment in hippocampal-dependent memory tasks (Ahn *et al.* 2006). These studies indicate a significant role for *Dyrk1A/mnb* in learning and memory. Mutant *Dyrk1A/mnb* mice have a decrease in brain size and changes in neuron density in selected brain regions (Fotaki *et al.* 2002). Alternatively, mice over-expressing *Dyrk1A/mnb* have an increase in brain weight (Branchi *et al.* 2004). Collectively, all of these studies suggest that *Dyrk1A/mnb* is involved in the neuropathological changes seen in patients with DS.

***Dyrk1A/mnb* studies in non-vertebrates**

The *Dyrk1A/mnb* enzyme is highly conserved evolutionarily, showing structural, enzymatic and functional similarities in organisms as diverse as yeast and humans (Becker and Joost 1999). In *Saccharomyces cerevisiae*, the *Dyrk1A/mnb* homologue is *Yak1p*, which negatively regulates cell growth by acting as an antagonist to the Ras/cAMP-dependent protein kinase pathway (Smith *et al.* 1998). In *Dictyostelium*, *YakA* is needed for starvation-induced growth arrest and initiation of a developmental response, as well as to mediate developmental events and facilitate exit from the cell cycle (Souza, *et al.* 1998). Three homologues of *Dyrk1A/mnb* have been examined in *Caenorhabditis elegans* termed *mbk-1*, *mbk-2* and *hpk-1*; the first is the most similar in

amino acid sequence to *Dyrk1A/mnb*. Although the loss of *mbk-1* has no obvious defects, over-expression of *mbk-1* causes behavioural defects in chemotaxis toward volatile chemoattractants, with the extent of the defects increasing with the gene dosage (Raich *et al.* 2003). The conservation of the *Dyrk1A/mnb* gene in organisms as unrelated as yeast and humans is a testament to the importance of its function.

mnb* studies in *Drosophila

Adult central nervous system development in *Drosophila melanogaster* involves a precise pattern of neuroblast proliferation. The *Dyrk1A/mnb* gene has been found to play a role in postembryonic neurogenesis by regulating the number and type of neurons that are formed. Flies with mutations in the *Dyrk1A/mnb* gene have significantly reduced optic lobes and central brain hemispheres due to a decrease in the number of cells generated during the proliferative process (Tejedor *et al.* 1995). This finding is consistent with the finding that mutant *Dyrk1A/mnb* mice have reduced brain size, and suggests a conserved mode of action determining brain size and normal growth in flies and mice (Lochhead *et al.* 2003). The *Dyrk1A/mnb* mutant flies also show learning and memory defects (Tejedor *et al.* 1995) similar to those found in humans (Coyle *et al.* 1986), showing the high conservation of the function of this gene in flies and humans.

Previous studies using *Drosophila* as a model organism have shown that *Dyrk1A/mnb* participates in development of the *Drosophila* eye and controls growth and survival through modification of insulin receptor signaling (Rotchford and Staveley, unpublished). Flies with *mnb* mutations were found to be phenotypically similar (ie. smaller than normal adult size) to flies with mutations in *akt* and over-expression of

foxo1. This showed that *mnb* is required for normal growth and may act through the *foxo1* protein to regulate cell size. Finally, over-expression of *mnb* was found to suppress loss of bristles and ommatidia in the eye caused by *foxo1* over-expression, suggesting that *mnb* negatively regulates *foxo1* (Rotchford 2006).

Huntington disease: Characteristics of the disease

Huntington disease (HD) is an autosomal dominantly inherited neurodegenerative disorder, affecting four to eight people per 100,000 (Harper 1992). Characteristic symptoms of the disease include cognitive, emotional and motor dysfunctions (Petersén *et al.* 1999). Cognitively, patients experience decreases in mental processes, reduced mental flexibility, and disturbances in memory and intellectual ability, which lead to dementia. Depression and manic-depression may accompany cognitive disturbances. Motor function defects are the most common and well known features of HD, and involve disturbances in both voluntary and involuntary movements. In addition, patients with juvenile HD have an increase rate of seizures, rigidity and tremors. Often patients display loss of body weight and muscle bulk. Symptoms often develop between the ages of 35 to 45, but age of onset can vary depending on the extent of genetic defect. In adult-onset HD, death usually occurs within 15 to 20 years of onset. Juvenile cases progress faster, with death occurring in 7 to 10 years. Pathologically, there is a loss of the GABAergic medium-sized spiny neurons in the striatum and cortex of the brain. These neurons innervate the substantia nigra and globus pallidus (Petersén *et al.* 1999). Aggregates of N-terminal fragments of mutant huntingtin form in the nucleus and cytoplasm of neurons in the brain (DiFiglia *et al.* 1997). The lack of treatment as well as

the great hardship for patients and their families highlights the importance of research on the mechanisms leading to HD.

Huntington disease: Genetic causes

HD is the result of an expanded CAG (cytosine, adenine, guanine) trinucleotide repeat in the gene *huntingtin* (*htt*), which encodes a protein of the same name whose routine function is relatively unknown (Ranen *et al.* 1995). The *htt* gene is located on chromosome 4 and was isolated using restriction-fragment length polymorphism mapping (Petersén *et al.* 1999). The *htt* protein has an amino terminal polyglutamine (polyQ) stretch and mutant forms have an expanse of Q's that is greater than 36 to 39 residues in length. Below this pathogenic threshold, individuals are unaffected (Snell *et al.* 1993; Rubinsztein *et al.* 1997). However, there are some cases where individuals with 36 to 39 repeats survive into old age without developing symptoms, suggesting that the HD mutation is not fully penetrant in some cases (Rubinsztein *et al.* 1997). Nevertheless, there is an inverse relationship between the age of onset and the severity of the disease with the number of residues present, such that repeats above 100 cause juvenile-onset of HD, whereas 40 to 50 residues are seen in adult-onset HD (Snell *et al.* 1993). High-repeat-number alleles tend to undergo germline mutations that increase repeat number, leading to an increase in the length of the polyQ stretch from one generation to the next. This means that the disease can be present at earlier ages in successive generations (Rubinsztein *et al.* 1997). Although the proximate genetic cause is known, there are still many unanswered questions about the mechanism that leads to the trinucleotide repeat/polyQ stretch manifesting as HD.

Identification and studies of huntingtin

The finding that amyloid-like protein aggregates form in brains of the transgenic mouse model of HD led researchers to investigate this aspect of the pathology in humans (Scherzinger *et al.* 1997). Nuclear inclusions had previously been found in HD patients, but they had not been investigated (Petersén *et al.* 1999). This led researchers to perform immunohistochemical mapping of the striatal biopsies taken from HD individuals. The nuclear inclusions contained mutant forms of the huntingtin protein, which led to further research on this protein in the pathogenesis of HD (Petersén *et al.* 1999).

Several research groups have established mouse models of HD, such as a yeast artificial chromosome (YAC) transgenic mouse containing an *htt* gene with 46 CAG repeats (Hodgson *et al.* 1999). This mouse shows no behavioural defects or neuronal loss, but it does have a reduction in long-term potentiation in hippocampal sections. Another mouse model with 46 repeats shows striatal neuronal inclusions and hyperactivity (Laforet *et al.* 1998). Additionally, invertebrate models, such as *C. elegans* have been engineered to express polyQ expanded *htt* proteins, and show that *htt* fragments cause nuclear aggregation and neurodegeneration (Morley *et al.* 2002). Studies on mice, rats, flies, *C. elegans* and pufferfish suggest that the gene is highly conserved, indicating an important cellular function (Sharp and Ross 1996). Many studies have shown a role for huntingtin in vesicle trafficking in which both normal and mutant huntingtin associate with clathrin-coated vesicles (Velier *et al.* 1998). Mutant *htt* forms aggregates that impede the function of the endocytic pathway (Qin *et al.* 2004). Despite these studies, the role of *htt* is not well understood and proteins that interact with it are under investigation.

Studies of huntingtin in Drosophila

There are a number of Drosophila models of polyglutamine expansion disease which display cell death and protein aggregation much like that seen in human HD patients (reviewed in Rubinsztein 2002). These models show declined motor performance, decreased flying ability and a reduced survival rate (Romero *et al.* 2008). Drosophila models have shown that polyglutamine proteins can cause defects in axonal transport (Gunawardena *et al.* 2003) and induce neuronal degeneration of photoreceptors (Jackson *et al.* 1998) that occurs over a period of about 20 days (Romero *et al.* 2008), or about two-thirds of a fly's life cycle. Attempts to find treatment for HD have been made using Drosophila as a model. Drosophila models of HD have been used to identify compounds that may be used as protein aggregation inhibitors (Desai *et al.* 2006). Lithium and rapamycin used in combination show greater protection against neurodegeneration in Drosophila than either treatment used on its own (Sarkar *et al.* 2008). Finally Drosophila models of HD can be used to test the effectiveness of drug combinations as testing is rapid and potentially therapeutic compounds can be administered in low doses, decreasing costs (Agrawai *et al.* 2005). Drosophila models of HD have proven to be effective models for testing the development of HD pathology as well as methods for treating the disease.

Huntingtin-interacting proteins

Understanding the functions of proteins that interact with htt may help clarify the cellular mechanisms by which polyglutamine expansion of the htt protein manifests as HD. The first of the huntingtin-interacting proteins discovered was huntingtin-associated

protein (Hap1) (Li *et al.* 1995). Hap1 could play a role in HD as its expression is higher in the brain than in other tissues. However, it is found in areas of the brain that are not affected in HD and the interaction of Hap1 with htt is increased with increased polyglutamine expansion. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) interacts with both normal and mutant huntingtin (Burke *et al.* 1996). GAPDH is a multifunctional enzyme that plays a role in glycolysis, DNA repair, and replication and endocytosis. GAPDH directly interacts with the polyglutamine tail of huntingtin. Huntingtin-interacting protein 2 (Hip2) was identified as a ubiquitin-conjugating enzyme, which may play a role in the ubiquitination of huntingtin (Kalchman *et al.* 1996). Although Hip2 is expressed in the brain regions affected in HD, there is no correlation between the length of polyglutamine residues and the extent of binding of Hip2. Huntingtin has been shown to form a complex with calmodulin (Bao *et al.* 1996). Normal huntingtin binds to calmodulin in a calcium-dependent manner, but mutant huntingtin has been demonstrated to not require calcium to interact with calmodulin.

Huntingtin-interacting protein 1 (Hip1) is perhaps the most interesting protein that binds to htt, due to its differential binding to normal and mutant htt (Kalchman *et al.* 1997; Wanker *et al.* 1997). Binding of Hip1 to huntingtin is reduced dramatically with polyglutamine expansion. The interaction between Hip1 and htt presumably occurs at the membrane, as both proteins are found bound there (Kalchman *et al.* 1997). *Hip1* is predominantly expressed in the central nervous system, and colocalizes with htt in neuronal cells and clathrin-coated vesicles (Kalchman *et al.* 1997; Wanker *et al.* 1997). Hence, *Hip1* is a strong candidate to reveal functional differences in normal and mutant htt.

***Hip1* characterization**

Hip1 is a 120kDa protein (Gervais *et al.* 2002) identified through a yeast-two hybrid screen because it binds to the amino terminus of huntingtin (Kalchman *et al.* 1997). Through comparative genomic analyses, *Hip1* was shown to have 45% amino acid sequence similarity to *Sla2p* (synthetic lethal with actin binding protein [ABP] 1), the cytoskeletal assembly gene of *S. cerevisiae* (Holtzman *et al.* 1993). *Sla2p* encodes a protein involved in vesicle trafficking, endocytosis and cortical actin cytoskeleton formation. In addition, *Hip1* is homologous to the *Caenorhabditis elegans* gene, *ZK370.3*, a gene of unknown function (Morley *et al.* 2002). The three proteins, *Hip1*, *Sla2p* and *ZK370.3*, have similar molecular masses and carboxy-terminal domains (Kalchman *et al.* 1997). Hip1 has four domains, an AP-180 N-terminal homology domain (ANTH), previously referred to as ENTH (epsin N-terminal homology domain), which allows the protein to interact with membranes that contain phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P₂), a pseudo-death effector domain (pDED) for protein-protein interactions, a central coiled-coil domain for clathrin binding and targeting to clathrin coated vesicles, and a C-terminal talin-like domain that binds to actin (Engqvist-Goldstein *et al.* 2001; Legendre-Guillemain *et al.* 2002; Hyun *et al.* 2004). This domain structure suggests that Hip1 plays a role mediating interactions between the cell membrane and/or membrane-bound vesicles and the cytoskeleton (Chen and Brodsky 2005). The complex structure of *Hip1* suggests that the Hip1 protein has complex functions and knowing the structure of Hip1 and functions of its domains may provide clues to the mechanisms that give rise to HD.

***Hip1* functions in cell death, cell growth and endocytosis**

Hip1 has been identified as a pro-apoptotic protein as over-expression leads of *Hip1* to caspase-dependent cell death (Hackam *et al.* 2000). Furthermore, Hip1 contains a domain that has a sequence homology to the death effector domains found in other pro-apoptotic proteins. When expressed alone in tissue culture, the pDED of Hip1 is sufficient to cause cell death, indicating the role of this domain in apoptosis. Interestingly, the severity of Hip1 toxicity is increased with a longer polyglutamine tail (Hackam *et al.* 2000). Polyglutamine expansion may cause the release of Hip1 to activate apoptosis in striatal neurons in a caspase-dependent manner. This theory is supported by the finding that the main pathological defect in HD patients is the loss of medium spiny neurons in the striatum (Gervais *et al.* 2002). Alterations in *Hip1* expression can lead to death of cells, much like the loss of neurons observed in HD brains.

Hip1 has been implicated as a contributor of tumour formation and growth. Expression of *Hip1* has been found in many primary human epithelial cancers, including breast, colon and prostate cancer, and is correlated with increasing aggressiveness of prostate cancer (Rao *et al.* 2003). Clearly, *Hip1* plays a significant role in the balance between cell death and the uncontrolled growth seen in cancer.

Hip1 has been found to participate in receptor-mediated endocytosis by promoting clathrin-coated vesicle assembly (Chen and Brodsky 2005). Clathrin-coated vesicles are important for selectively transporting proteins for receptor mediated endocytosis, a process that ensures the fast and specific retrieval of synaptic vesicle membranes. The clathrin molecule has a triskelion shape and is composed of both heavy and light clathrin

chains (Chen and Brodsky 2005). Trimerized heavy chains, each with a covalently-bound light chain, form polyhedral lattice-coated triskelia. Typically, proteins affect receptor-mediated endocytosis by influencing coat assembly, membrane association, membrane fission and uncoating by binding to heavy chains (Chen and Brodsky 2005). Hip1 has been identified to bind to the clathrin adapter protein (AP2) and the clathrin heavy chain (Metzler *et al.* 2001). The light chains function to prevent spontaneous assembly and promote controlled assembly by other regulatory proteins. Hip1 is one of the proteins that bind to light chains (Chen and Brodsky 2005). In addition, because Hip1 binds both clathrin and PtdIns (4, 5) P₂, it is thought to link the triskelia to the lipid membrane (Metzler *et al.* 2001). According to these studies, Hip1 certainly plays a role in receptor-mediated endocytosis, but the specific function of Hip1 has not yet been described in detail.

Study of *Hip1* in *Drosophila*

To facilitate the biological characterization of *Hip1*, the *Drosophila* homologue of *Hip1* was isolated in our laboratory (Moore *et al.* 2008). Compared to humans, the *Drosophila* genome has a highly conserved *Hip1* gene that contains the AP180 N-terminal homology (ANTH) domain, pseudo death effector domain (pDED) and the talin-like domain. There are two versions of the putative protein, a full length version and an alternative transcript that yields a version missing the N-terminal ANTH domain, referred to as Hip1 Δ ANTH. *Hip1* regulates neurogenesis in flies as revealed by microchaetae analysis in the adult dorsal notum (Moore *et al.* 2008). While over-expression of full length *Hip1* decreases microchaetae bristle formation, the Δ ANTH version, presumably

acts to interfere through an inhibitory activity act, produces increased bristle density on the notum (Moore *et al.* 2008).. Since the number of bristles can be correlated to the number of sensory bristles formed, this indicates a dual-regulatory role for *Hip1* in neurogenesis (Romain *et al.* 2001; Moore *et al.* 2008). The mechanism by which *Hip1* influences neurogenesis seems to be through the non-canonical *Notch* signaling pathway, where *deltex* appears to have the greatest influence (Moore *et al.* 2008). The study by Moore *et al.* was the first account of a role for *Hip1* in neurogenesis.

A link between *Hip1* and *Dyrk1A/mnb*

A biochemical interaction has been identified between *Hip1* and *Dyrk1A/mnb* using the yeast two-hybrid assay (Kang *et al.*, 2005). During neuronal differentiation of embryonic hippocampal neuroprogenitor H19-7 cells, *Dyrk1A/mnb* selectively bound to and phosphorylated *Hip1*, which was induced by the addition of bFGF, a fibroblast growth factor. Strong complexes formed between *Hip1* and *Dyrk1A/mnb*. The binding of these two proteins resulted in blockage of *Hip1*-induced cell death and contributed to neurite outgrowth. Upon the addition of etoposide phosphate, the binding decreased and phosphorylation of *Hip1* diminished. No longer bound to *Dyrk1A*, *Hip1* was free to bind to caspase-3 to activate cell death. On the basis of a clear, functional interaction established in tissue culture cells, the current study aims to investigate the biological interaction between the *Dyrk1A/mnb*, and *Hip1* in *Drosophila melanogaster* as a model organism.

Goals of this research

This project will utilize *Drosophila melanogaster* to study the biological effects of *mnb* and *Hip1* gene expression. Experiments that examined *Dyrk1A/mnb* ectopic expression in *Drosophila* have shown that *Dyrk1A/mnb* controls growth through modification of insulin receptor signaling (Rotchford 2006; Rotchford and Staveley, unpublished). The first goal of the current study is to investigate a potential role for components of the insulin receptor pathway and *Dyrk1A/mnb* in neurogenesis. Specifically, I will direct the expression of these genes using the *pannier*- and *apterous* *Gal4* lines to the dorsal notum and perform biometric analysis on the tissue. Second, previous studies in our laboratory have characterized the role of the two versions of the Hip1 protein, a full length version containing a lipid-binding domain, and a truncated version lacking the lipid-binding domain, Hip1 Δ ANTH, in *Drosophila* neurogenesis (Moores *et al.* 2008). My goal is to analyze the effect of *Hip1* on eye development by directing the expression of *Hip1* to the developing eye using the *GMR* transgene and performing biometric analysis. Finally, as a biochemical link has been made between *mnb* and *Hip1*, the biological consequences of aspects of this proposed interaction will be studied in the *Drosophila* eye by expressing the *mnb* and *Hip1* genes together in a *foxo1*-sensitized background and analyzing the eyes biometrically. Using the *Drosophila* model will allow the characterization of subtle alterations in the development and growth of the adult eye and notum.

Materials and Methods

Investigating the role of *mnb*, *akt*, and *foxo1* in neurogenesis

Drosophila stocks

The *y w; apterousGal4/CyO* (*apGal4*) and *y w; pannierGal4/TM3, UAS, y⁺* (*pnrGal4*) transgenics (Calleja *et al.* 1996) were obtained from Bloomington Drosophila Stock Center (University of Indiana, Bloomington). The *y w^{67c23} mnb^{EY14320}* (*UASmnb*) (Bellen *et al.* 2004) stocks were created by members of the Drosophila Gene Disruption Project and provided by Bloomington Drosophila Stock Center. The *w; UASAkt^{1.1}/CyO* line (*UASakt*) was described in Staveley *et al.* (1998), and the inducible murine *foxo1* homologue, *w; UASfoxo1/CyO* (*UASfoxo*) was described in Kramer *et al.* (2003). The *w; UASlacZ⁴⁻¹⁻²* (*UASlacZ*) (Brand and Perrimon 1994) and the *w; UASGFP* (*UASGFP*) (Yeh *et al.* 1995) control lines were obtained from the Bloomington Drosophila Stock Center. Table 1 summarizes these genotypes, their sources, and abbreviations used throughout the thesis.

Table 1. The genotypes of stocks used to study the potential role of *mnb*, *akt*, and *foxo1* in neurogenesis, their sources, and abbreviations used throughout the thesis.

Full Genotype	Reference	Abbreviation
Transgenic transcription factors		
<i>y w; apterousGal4/CyO</i>	Calleja <i>et al.</i> 1996	<i>apGal4</i>
<i>y w; pannierGal4/TM3 UAS, y⁺</i>	Calleja <i>et al.</i> 1996	<i>pnrGal4</i>
Control genes		
<i>w; UASGFP</i>	Yeh <i>et al.</i> 1995	<i>UASGFP</i>
<i>w; UASlacZ⁴⁻¹⁻²</i>	Brand and Perrimon 1994	<i>UASlacZ</i>
Experimental genes		
<i>y w^{67c23} mnb^{EY14320}</i>	Bellen <i>et al.</i> 2004	<i>UASmnmb</i>
<i>w; UASAkt^{1.1}/CyO</i>	Staveley <i>et al.</i> 1998	<i>UASakt</i>
<i>w; UASfoxo1/CyO</i>	Kramer <i>et al.</i> 2003	<i>UASfoxo1</i>

Drosophila culture

To investigate the roles of *mnb* and components of the insulin signaling pathway, *akt* and *foxo1*, in neurogenesis, four to six males carrying the *UASmnb*, *UASakt*, and *UASfoxo1* responsive genes were each crossed to eight to ten virgin females of the *apGal4* and *pnrGal4* fly lines. Control crosses were set up using four to six males of *UASlacZ* and *UASGFP*, which were crossed to eight to ten virgin females from both the *apGal4* and *pnrGal4* fly lines. Crosses were maintained on standard cornmeal yeast molasses agar media at 25°C. Parental flies were transferred to fresh media after four days to increase production of progeny. Critical class males and females were collected based on an absence of *CyO* for *apGal4* crosses and *TM3;UAS, y⁺* for *pnrGal4* crosses (Figure 1 and 2). Critical class individuals were aged in fresh vials for three to five days, then placed in 1.5 mL microcentrifuge tubes and frozen at -70°C.




Figure 1. Schematic diagram of crosses made to examine the potential effects of *mn*, *akt* and *foxo1* on neurogenesis using the *apterousGal4* transgene. Crosses to *UASlacZ* (a) and *UASGFP* (b) were conducted as controls. Experimental crosses were performed for *UASmn* (c), *UASakt* (d) and *UASfoxo1* (e). †Note: no critical class offspring were recovered from this cross. * Note: only female progeny were collected from this cross.

Biometric analysis of dorsal notum microchaetae

The density of microchaetae on the dorsal notum has been characterized in *Notch* mutants as a measure of neurogenesis (Romain *et al.* 2001). Flies were mounted on aluminum scanning electron microscope studs with the dorsal notum facing upward. Studs were desiccated overnight and then gold coated using either a S150 Gold Sputter Coater or an EMSK550 Gold Sputterer. Samples were photographed using a Hitachi 570 scanning electron microscope or a FEI Quanta 400 environmental scanning electron microscope. Micrographs taken on the Hitachi 570 scanning electron microscope were photographed at 80X magnification, while those taken on the FEI Quanta 400 environmental scanning electron microscope were photographed at 250 X magnification due to the differences in the calibrations of the microscopes. Micrographs were analyzed using Image J digital image analysis software (<http://rsbweb.nih.gov/ij/>) (Abramoff *et al.* 2004). The number of microchaetae on the dorsal notum were counted for each image. Total dorsal notum area (μm^2) was also calculated. The microchaetae counts and notum area were used to calculate the bristle density, expressed as number of microchaetae per $100 \mu\text{m}^2$. Bristle density values were exported into the GraphPad Prism 4 program (by GraphPad Software, Inc.) and mean \pm standard error of the mean (SEM) are plotted for each individual genotype. Males and females were analyzed separately due to expected phenotypic differences in size. Groups were subjected to a one-way ANOVA analysis with Neuman-Keuls post-tests, using GraphPad Prism 4, to determine significance between pairs.

The potential role of *Huntingtin interacting protein-1* and *minibrain* in eye development using *GMRGal4*

Drosophila stocks

The *UASmnb* stock was described above. The two independent isolates of the full length version of the *Hip1* gene, *w; L/CyO; UASHip1^{L-2}/TM3,Sb* (*UASHip1^{L-2}*) and *w; L/CyO; UASHip1^{L-6}/TM3,Sb*, (*UASHip1^{L-6}*) and the two isolates of the amino terminal truncated form of the *Hip1* gene, *UASHip1^{11.2}* and *UASHip1^{5.2}* (referred to as *Hip-1ΔANTH*) were described in Moores (2006). Both full length versions of *Hip1* were crossed to *w; Ly/TM6B* (obtained from Staveley laboratory stock) to eliminate the second chromosome balancer. Male and female progeny with *CyO* and *TM6B* were backcrossed to each other to obtain *w; UASHip1^{L-2}/TM6B* and *w; UASHip1^{L-6}/TM6B* lines (Appendix 1). The *w; GMRGal4¹²* transgenic line was described in Freeman (1996). Table 2 summarizes these genotypes and their sources.

Table 2. The genotypes of stocks used to study the potential role of *Hip1*, *Hip1*Δ*ANTH* and *mnb* in eye development, their sources, and abbreviations used throughout the thesis.

Full Genotype	Reference	Abbreviation
Transgenic transcription factors		
<i>w</i> ; <i>GMRGal4</i> ¹²	Freeman 1996	<i>GMRGal4</i>
Control genes		
<i>w</i> ; <i>UASGFP</i>	Yeh <i>et al.</i> 1995	<i>UASGFP</i>
<i>w</i> ; <i>UASlacZ</i> ⁴⁻¹⁻²	Brand and Perrimon 1994	<i>UASlacZ</i>
Experimental genes		
<i>w</i> ; <i>UASHip1</i> ^{L-2} / <i>TM6B</i>	Moore 2006	<i>UASHip1</i> ^{L-2}
<i>w</i> ; <i>UASHip1</i> ^{L-6} / <i>TM6B</i>	Moore 2006	<i>UASHip1</i> ^{L-6}
<i>w</i> ; <i>UASHip1</i> ^{5.2}	Moore 2006	<i>UASHip1</i> ^{5.2}
<i>w</i> ; +; <i>UASHip1</i> ^{11.2}	Moore 2006	<i>UASHip1</i> ^{11.2}
<i>y w</i> ^{67c23} <i>mnbc</i> ^{EY14320}	Bellen <i>et al.</i> 2004	<i>UASmnbc</i>

Drosophila culture

To examine the role of *mnb* in eye development, two to four males of *UASmnb* were crossed to six to eight virgin females of *GMRGal4*. To investigate the role of both the full length and truncated versions of the *Hip1* gene on eye development, two to four males of *UASHip1^{L-2}*, *UASHip1^{L-6}*, *UASHip1^{11.2}* and *UASHip1^{5.2}* lines were each crossed to four to six virgin female *GMRGal4*. Control crosses were conducted using two to four males of *UASlacZ* and *UASGFP* and four to six virgin females from the *GMRGal4* line (Figure 3). Crosses were maintained at 25°C on standard cornmeal yeast molasses agar media. Parental flies were transferred to fresh media after four days to increase production of progeny. All progeny were collected for *GMRGal4* crosses as there was no balancer chromosome to select against. Collected flies were aged in fresh vials for three to five days, placed in microcentrifuge tubes and frozen at -70°C.




Figure 3. Schematic diagram of crosses made to examine the potential effects of *Hip1*, *Hip1* Δ *ANTH* and *mn* in eye development using the *GMRGal4* transgene.

Crosses to *UASlacZ* (a) and *UASGFP* (b) were conducted as controls. Experimental crosses were performed for *UASmn* (c), *UASHip1^{L-2}* (d), *UASHip1^{L-6}* (e), *UASHip1^{5.2}* (f) and *UASHip1^{11.2}* (g).

Biometric analysis of the adult eye

Analysis of adult *Drosophila* eye structures has been used to reveal subtle aspects of growth and cell survival (for example Kramer *et al.* 2003). Flies were mounted on aluminum scanning electron microscope studs using double sided sticky tape with the left eye facing upward. Studs were then desiccated overnight and gold coated using either a S150 Gold Sputter Coater or an EMSK550 Gold Sputterer. Eyes were photographed using a Hitachi 570 scanning electron microscope or a FEI Quanta 400 environmental scanning electron microscope. Micrographs taken on the Hitachi 570 scanning electron microscope were photographed at 170X magnification, while those taken on the FEI Quanta 400 environmental scanning electron microscope were photographed at 450X magnification due to differences in the calibration of the microscopes. Micrographs were analyzed using Image J digital image analysis software (<http://rsbweb.nih.gov/ij/>) (Abramoff *et al.* 2004). The number of ommatidia and number of bristles were counted for each image. The area (in μm^2) of seven ommatidia in a “honey comb” pattern was determined for three sets and the average area per ommatidia was calculated. Ommatidia number, bristle number and area of ommatidia values were exported into the GraphPad Prism 4 program (by GraphPad Software, Inc.) and means \pm standard error of the means (SEM) were plotted for each of the three parameters for each individual genotype. Male and female flies were analyzed separately due to expected phenotypic differences in size. Using GraphPad Prism 4, groups were subjected to a one-way ANOVA analysis with Neuman-Keuls post-tests to determine significance between pairs and mean \pm standard error of the mean (SEM) were plotted for each individual genotype.

Interaction of *foxo1* with *mnb* and *Hip1*

Drosophila stocks, culture and analysis

The *w*; *GMRGal4 UASfoxo1/CyO* (*GMRGal4 UASfoxo1*) recombinant line was described in Kramer *et al.* (2003). Additional stocks used were as above in “The potential role of *Huntingtin interacting protein-1* and *minibrain* in eye development using *GMRGal4*” section. To investigate the interaction of *foxo1* with *mnb* and *Hip1*, two to four males of *GMRGal4 UASfoxo1/CyO* were crossed to six to eight virgin females of *UASGFP*, both versions of *UASHip1*, both versions of *UASHip1ΔANTH*, and *mnb*. Crosses were maintained at 25°C on standard cornmeal yeast molasses agar media. Parental flies were transferred to fresh media every four days to increase production of progeny. Both male and female progeny were collected based on a lack of *CyO* (Figure 4). Collected flies were aged in fresh vials for three to five days, placed in 1.5 ml microcentrifuge tubes and frozen at -70°C. Analysis was conducted as per above in the “Biometric analysis of dorsal notum microchaetae” and “Biometric analysis of the adult eye” sections.




Figure 4. Schematic diagram of crosses made to examine the potential effects of *Hip1*, *Hip1* Δ *ANTH* and *mnb* in eye development with the *GMRGal4* and *UASfoxo1* transgenes. Crosses to *UASGFP* (a) were conducted as controls. Experimental crosses were performed for *UASmnb* (b), *UASHip1^{L-2}* (c), *UASHip1^{L-6}* (d), *UASHip1^{5.2}* (e) and *UASHip1^{11.2}* (f).

Interaction of *mnb* and *Hip1* with each other

Drosophila stocks

The *w; L/CyO; Ki/TM3,Sb* line was created and obtained from B. E. Staveley (Memorial University of Newfoundland). Additional stocks used were as above.

Generation of *mnb; Hip1* lines

To investigate the possible interactions between *mnb* and *Hip1*, combinations of *mnb* transgenics with both versions of *Hip1* were generated as follows:

For *Hip1* on the third chromosome

Eight to ten virgin females of *UASmnb* were crossed to four to six males of *w; Ly/TM6B*. Males were selected with either *Ly* or *TM6B* and crossed to *UASmnb* virgin females. The *UASmnb; Ly/+* progeny were crossed to *UASmnb; +/TM6B* progeny to obtain *UASmnb; Ly/TM6B* flies. The *UASmnb; Ly/TM6B* flies were then crossed together to establish a stock line that can be used in future crosses (Figure 5). Six to eight virgin females of *UASmnb; Ly/TM6B* were crossed to four males of *UAS Hip1^{L-2}*, *UAS Hip1^{L-6}*, and *UAS Hip1^{11.2}*. Male progeny was collected on the basis of *TM6B* presence, and crossed back to virgins with mother-like genotype (*UASmnb; Ly/TM6B*). Virgin females and males were collected on the basis of *TM6B* presence and crossed together to establish *UASmnb; UASHip1^{L-2}*, *UASmnb; UASHip1^{L-6}* and *UASmnb; UASHip1^{11.2}* combination lines (Figure 6).




Figure 5. Schematic diagram of crosses made to establish *UASmnb; Ly/TM6B* stocks to examine the potential interaction of *Hip1* and *Hip1 Δ ANTH* with *mnb* in eye development with the *GMRGal4* and *UASfoxo1* transgenes.




Figure 6. Schematic diagram of crosses made to establish *UASmnbl; UASHip1* combination stock lines for *Hip1* on the third chromosome that will be used to examine the potential interaction of *Hip1* and *Hip1*Δ*ANTH* with *mnbl* in eye development with the *GMRGal4* and *UASfoxo1* transgenes.

For *Hip1* on the second chromosome

Eight to ten virgin females of *UASmnb* were crossed to four to six males of w; *L/CyO; Ki/TM3, Sb*. Males were selected with either *L/+; +/TM3, Sb* or *+/CyO; +/TM3, Sb* and crossed to *UASmnb* virgin females. The *UASmnb; L/+; +/TM3, Sb* progeny were crossed to *UASmnb; +/CyO; +/TM3, Sb* progeny to obtain *UASmnb; L/CyO; +/TM3, Sb* flies. The *UASmnb; L/CyO; +/TM3, Sb* flies were then crossed together to establish a stock line that can be used in future crosses (Figure 7). The *UASmnb; L/CyO; +/TM3, Sb* flies were crossed to *UASHip1^{5.2}*. Male progeny was selected for *CyO* and *TM3, Sb* or *CyO* alone, and crossed back to virgins with mother-like genotype (*UASmnb; L/CyO; +/TM3, Sb*). Virgin females and males were collected on the basis of *CyO* presence and crossed together to establish *UASmnb; UASHip1^{5.2}* combination lines (Figure 8).




Figure 7. Schematic diagram of crosses made to establish *UASmnb; L/CyO; +/TM3, Sb* stocks to examine the potential interaction of *Hip1* and *Hip1*ΔANTH with *mnb* in eye development with the *GMRGal4* and *UASfoxo1* transgenes.




Figure 8. Schematic diagram of crosses made to establish *UASmnbl; UASHip1* combination stock lines for *Hip1* on the second chromosome that will be used to examine the potential interaction of *Hip1* and *Hip1 Δ ANTH* with *mnbl* in eye development with the *GMRGal4* and *UASfoxo1* transgenes.

Drosophila culture and analysis

To investigate the interaction of *mnb* and *Hip1* together with *foxo1*, two to four males of *GMRGal4 UASfoxo1/CyO* were crossed to six to eight virgin females of *UASmnb; UASHip1^{L-2}*, *UASmnb; UASHip1^{L-6}*, *UASmnb; UASHip1^{5.2}* and *UASmnb; UASHip1^{11.2}*. Crosses were maintained at 25°C on standard cornmeal yeast molasses agar media. Parental flies were transferred to fresh media at four days to increase production of progeny. Both male and female progeny were collected based on a lack of *CyO* (Figure 9). Collected flies were aged in fresh vials for three to five days, placed in 1.5 ml microcentrifuge tubes and frozen at -70°C.

Analysis was conducted as above.




Figure 9. Schematic diagram of crosses made to examine the potential effects of *Hip1* and *Hip1*ΔANTH with *mnb* in eye development with the *GMRGal4* and *UASfoxo1* transgenes. Experimental crosses were performed for *UASmnb; UASHip1^{L-2}* (a), *UASmnb; UASHip1^{L-6}* (b), *UASmnb; UASHip1^{5.2}* (c) and *UASmnb; UASHip1^{11.2}* (d).


Results

Investigation of neurogenesis in the dorsal notum


*there is no phenotypic effect of *mnb* on neurogenesis in the dorsal notum*

With the demonstrated role for *Hip1* in neurogenesis and the intriguing interaction between *mnb* and *Hip1* in cell culture, this study investigates the role of *mnb* on neurogenesis, using *pnrGal4* and *apGal4* to direct the over-expression of genes throughout the dorsal notum. The expression of *pannier* is greatest at the midline and diminishes laterally while the expression of *apterous* is highest laterally and is lowest at the midline (Calleja *et al.* 1996). Microchaetae density per 100 μm^2 was determined for electron micrographs of males and females of each genotype. As well, macrochaetae gross morphology was observed as well as differences in position and number on the dorsal notum. Results are summarized in Table 3. There was no statistically significant difference in microchaetae density in response to *mnb* by *apterousGal4* compared to controls in females based on a one-way ANOVA (Figure 10). Similarly, expression of *mnb* by *pannierGal4* in females showed no differences in microchaetae density compared to controls based on a one-way ANOVA (Figure 11). It should be noted that no statistically significant difference between the *lacZ* and *GFP* controls using either *apterousGal4* or *pannierGal4* based on a one-way ANOVA (Figures 10 and 11). Results are summarized in Table 3. There was no difference in the gross morphology, position or number of macrochaetae in response to *mnb* as shown in the electron micrographs in Figures 10 and 11.


A



GFP



lacZ



mnbl

B





Figure 10. Biometric analysis of a potential role of *mnb* in neurogenesis with the *apterousGal4* transgene in females. Directed expression of *mnb* in the dorsal notum has no phenotypic effect on microchaetae density based on a one-way ANOVA (n=30).


Micrographs of dorsal notums are shown in A. Graphic representations of microchaetae density is shown in B (values represent mean \pm SEM). The genotypes are as follows:

***GFP* UAS*GFP*/*apGal4*, *lacZ* UAS*lacZ*/*apGal4*, *mnb* UAS*mnb*^{EY14320}/+; *apGal4*/+.** Note: *GFP* and *lacZ* controls are the same as those used for *apterousGal4* driving the expression of *akt*.


A



GFP



lacZ



mnbl

B





Figure 11. Biometric analysis of a potential role of *mnb* in neurogenesis with the *pannierGal4* transgene in females. Directed expression of *mnb* in the dorsal notum had no phenotypic effect on microchaetae density based on a one-way ANOVA (n=30). Micrographs of dorsal notums are shown in A. Graphic representations of microchaetae density are shown in B (values represent mean \pm SEM). The genotypes are as follows: *GFP* *UASGFP*/+; *pnrGal4*/+, *lacZ* *UASlacZ*/+; *pnrGal4*/+, *mnb* *UASmnb*^{EY14320}/+; *pnrGal4*/+. Note: *GFP* and *lacZ* controls are the same as those used for *pannierGal4* driving the expression of *akt* and *foxo1*.


akt over-expression affects neurogenesis in the dorsal notum but *foxo1* over-expression does not show a phenotypic effect

The potential roles of *akt* and *foxo1*, two well-studied insulin receptor signaling components, were investigated in neurogenesis. The *pannierGal4* and *apterousGal4* transgenes were used to direct the over-expression of *akt* and *foxo1* throughout the dorsal notum. Microchaetae density was determined for electron micrographs of males and females except that in flies with *apterousGal4* driving *foxo1* did not survive and could not be analyzed. As well, differences in gross morphology, position and number of macrochaetae on the dorsal notum were noted. There was no statistically significant difference, based on a one-way ANOVA, in microchaetae density in response to *akt* expression by *apterousGal4* compared to controls for either males or females (Figures 12 and 13). Expression of *foxo1* by *pannierGal4* showed no differences in microchaetae density compared to controls for males and females based on a one-way ANOVA (Figures 14 and 15). However, there was an increase in the microchaetae density with *akt* expression by *pannierGal4* compared to both the *lacZ* and *GFP* controls in females but not males. Although not different from the controls, the microchaetae density of female flies expressing *foxo1* with *pannierGal4* is significantly lower than the microchaetae density of flies expressing *akt* (Figure 14). Comparisons are summarized in Table 3. There was no difference in the gross morphology, position or number of macrochaetae in response to *akt* or *foxo1* expression under either transgene as seen in the electron micrographs shown in Figures 12 to 15.


A



GFP



lacZ



akt

B






Figure 12. Biometric analysis of a potential role of *akt* in neurogenesis with the *apterousGal4* transgene in females. Directed expression of *akt* in the dorsal notum has no phenotypic effect on microchaetae density based on a one-way ANOVA (n=30). Micrographs of dorsal notums are shown in A. Graphic representations of microchaetae density are shown in B (values represent mean \pm SEM). The genotypes are as follows: **GFP** *UASGFP/apGal4*, **lacZ** *UASlacZ/apGal4*, **akt** *UASakt/apGal4*. Note: *GFP* and *lacZ* controls are the same as those used for *apterousGal4* driving *mnb*.


A



GFP



lacZ



akt

B





Figure 13. Biometric analysis of a potential role of *akt* in neurogenesis with the *apterousGal4* transgene in males. Directed expression of *akt* in the dorsal notum has no phenotypic effect on microchaetae density based on a one-way ANOVA (n=30).


Micrographs of dorsal notums are shown in A. Graphic representations of microchaetae density are shown in B (values represent mean \pm SEM). The genotypes are as follows:

***GFP* UAS*GFP*/+; *pnrGal4*/+, *lacZ* UAS*lacZ*/+; *pnrGal4*/+, *akt* UAS*akt*/+; *pnrGal4*/+.**


A




GFP



lacZ



akt



foxo

B






Figure 14. Biometric analysis of a potential role of *akt* and *foxo1* on neurogenesis with the *pannierGal4* transgene in females. Directed expression of *foxo1* in the dorsal notum has no phenotypic effect on microchaetae density based on a one-way ANOVA (n=20), while expression of *akt* increases microchaetae density compared to both *GFP* and *lacZ* controls (n=30) ($p < 0.01$ by Neuman-Keuls post-test). Micrographs of dorsal notums are shown in A. Graphic representations of microchaetae density are shown in B (values represent mean \pm SEM). The genotypes are as follows: ***GFP* UAS*GFP*/+;** *pnrGal4*/+, ***lacZ* UAS*lacZ*/+;** *pnrGal4*/+, ***akt* UAS*akt*/+;** *pnrGal4*/+, ***foxo1* UAS*foxo1*/+;** *pnrGal4*/+. Note: *GFP* and *lacZ* controls are the same as those used for *pannierGal4* driving *mnf*. Bars with dissimilar superscripts indicate groups that differ significantly.


A




GFP



lacZ



akt



foxo

B




Figure 15. Biometric analysis of a potential role of *akt* and *foxo1* in neurogenesis with the *pannierGal4* transgene in males. Directed expression of *akt* (n=30) and *foxo1* (n=7) in the dorsal notum has no phenotypic effect on microchaetae density based on a one-way ANOVA. Micrographs of dorsal notums are shown in A. Graphic representations of microchaetae density are shown in B (values represent mean \pm SEM). The genotypes are as follows: ***GFP UASGFP/+; pnrGal4/+***, ***lacZ UASlacZ/+; pnrGal4/+***, ***akt UASakt/+; pnrGal4/+***, ***foxo1 UASfoxo1/+; pnrGal4/+***.

Table 3. Comparison of microchaetae density changes in the dorsal notum in response to *mnb*, *akt*, and *foxo1* over-expression.

Comparison	Transcription factor	Sex	Significance
<i>akt</i> vs. <i>GFP</i>	<i>apterous</i>	F	NS
		M	NS
<i>akt</i> vs. <i>lacZ</i>	<i>apterous</i>	F	NS
		M	NS
<i>foxo1</i> vs. <i>GFP</i>	<i>apterous</i>	F	flies died
		M	flies died
<i>foxo1</i> vs. <i>lacZ</i>	<i>apterous</i>	F	flies died
		M	flies died
<i>akt</i> vs. <i>GFP</i>	<i>pannier</i>	F	↑ p < 0.001
		M	NS
<i>akt</i> vs. <i>lacZ</i>	<i>pannier</i>	F	↑ p < 0.001
		M	NS
<i>foxo1</i> vs. <i>GFP</i>	<i>pannier</i>	F	NS
		M	NS
<i>foxo1</i> vs. <i>lacZ</i>	<i>pannier</i>	F	NS
		M	NS
<i>akt</i> vs. <i>foxo1</i>	<i>apterous</i>	F	NA
		M	NA
<i>akt</i> vs. <i>foxo1</i>	<i>pannier</i>	F	↑ p < 0.01
		M	NS
<i>mnb</i> vs. <i>GFP</i>	<i>apterous</i>	F	NS
<i>mnb</i> vs. <i>lacZ</i>	<i>apterous</i>	F	NS
<i>mnb</i> vs. <i>GFP</i>	<i>pannier</i>	F	NS
<i>mnb</i> vs. <i>lacZ</i>	<i>pannier</i>	F	NS
<i>GFP</i> vs. <i>lacZ</i>	<i>apterous</i>	F	NS
		M	NS
<i>GFP</i> vs. <i>lacZ</i>	<i>pannier</i>	F	NS
		M	NS

Arrows indicate increase (↑) or decrease (↓) in treatment.

p values based on Neuman-Keuls post tests

NS= not significant

F=female


M=male

The potential role of *Huntingtin interacting protein-1* and *mnb* in eye development using *GMRGal4*

Hip1 has no phenotypic effect on eye development under standard growth conditions

As *mnb* has been found to play a role in eye development, the role of *Hip1* on eye development was investigated. The *GMRGal4* transgene was used to direct the over-expression of genes throughout the developing eye. *GMRGal4* directs the expression of genes posterior to the morphogenetic furrow, a dorsoventral indentation, late in development (Freeman 1996). Ommatidia number, bristle number and ommatidia area were determined for electron micrographs of males and females. There was no difference within males or females in ommatidia number, bristle number or ommatidia area for either of the full length versions of *Hip1*, *Hip1^{L-2}* and *Hip1^{L-6}* or the truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* or *Hip1ΔANTH^{11.2}*, based on a one-way ANOVA (Figures 16 and 17). Based on a one-way ANOVA, there was no difference between the two full length versions of *Hip1* or between the two truncated versions of *Hip1* (Figures 16 and 17). The controls, *GFP* and *lacZ* were not different in males or females based on one-way ANOVA, to suggest that either of these are good controls. Electron micrographs of eyes demonstrate the similarities among experimental conditions and controls (Figures 16 and 17).

A




GFP




lacZ



Hip1^{L-2}



Hip1^{L-6}



Hip1 Δ ANTH^{5.2}



Hip1 Δ ANTH^{11.2}

B






Figure 16. Biometric analysis of a potential role of *Hip1* and *Hip1ΔANTH* on eye development using the *GMRGal4* transgene in females. Directed expression of two full length versions of *Hip1*, *Hip1^{L-2}* and *Hip1^{L-6}* and two truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{11.2}*. *Hip1* in the eye has no phenotypic effect on bristle number (n=10), ommatidia number (n=10) or ommatidia area (n=10) compared to controls based on a one-way ANOVA. Micrographs of eyes are shown in A. Graphic representations of ommatidia area, bristle number and ommatidia size are shown in B (values represent mean ± SEM). The genotypes are as follows: ***GFP*** *UASGFP/GMRGal4, lacZ UASlacZ/GMRGal4, Hip1^{L-2} UASHip1^{L-2}/+; GMRGal4/+*, ***Hip1^{L-6} UASHip1^{L-6}/+; GMRGal4/+***, ***Hip1ΔANTH^{5.2} UASHip1^{5.2}/GMRGal4***, ***Hip1ΔANTH^{11.2} UASHip1^{11.2}/+; GMRGal4/+***.

A



GFP



lacZ



Hip1^{L-2}



Hip1^{L-6}



Hip1ΔANTH^{5.2}



Hip1ΔANTH^{11.2}

B







Figure 17. Biometric analysis of a potential role of *Hip1* and *Hip1* Δ *ANTH* on eye development using the *GMRGal4* transgene in males. Directed expression of two full length versions of *Hip1*, *Hip1*^{L-2} and *Hip1*^{L-6}, two truncated versions of *Hip1*, *Hip1* Δ *ANTH*^{5.2} and *Hip1* Δ *ANTH*^{11.2} have no phenotypic effect on bristle number (n=10), ommatidia number (n=10) and ommatidia area (n=10) compared to controls based on a one-way ANOVA. Micrographs of eyes are shown in A. Graphic representations of ommatidia area, bristle number and ommatidia number are shown in B (values represent mean \pm SEM). The genotypes are as follows: ***GFP* UAS*GFP*/*GMRGal4*, *lacZ* UAS*lacZ*/*GMRGal4*, *Hip1*^{L-2} UAS*Hip1*^{L-2}/+; *GMRGal4*/+, *Hip1*^{L-6} UAS*Hip1*^{L-6}/+; *GMRGal4*/+, *Hip1* Δ *ANTH*^{5.2} UAS*Hip1*^{5.2}/*GMRGal4*, *Hip1* Δ *ANTH*^{11.2} UAS*Hip1*^{11.2}/+; *GMRGal4*/+.**


mnb has no phenotypic affect on eye development

Studies in our laboratory have found that the over-expression of *mnb* along with *foxo1* over-expression disrupts wild-type eye development (Rotchford 2006). However, the directed expression of *mnb* has not been carefully studied in eye development. This study utilized the *GMRGal4* transgene to direct the over-expression of *mnb* throughout the developing eye. Ommatidia number, bristle number and ommatidia area were determined for electron micrographs of females only. There was no difference in ommatidia number, bristle number for ommatidia area formed on the eye between experimental samples and controls based on one-way ANOVA (Figure 18). Electron micrographs show the similarity between *mnb* and control eyes (Figure 18).


A



GFP



lacZ



mnb

B






Figure 18. Biometric analysis of a potential role of *mnb* in eye development using the *GMRGal4* transgene in females. The directed expression of *mnb* has no phenotypic effect on ommatidia area (n=10), bristle number (n=10), or ommatidia number (n=10). Micrographs of eyes are shown in A. Graphic representations of ommatidia area, bristle number and ommatidia number are shown in B (values represent mean \pm SEM). The genotypes are as follows: ***GFP UASGFP/GMRGal4, lacZ UASlacZ/GMRGal4, mnbnb*** *UASmnbnb^{EY14320}/+; GMRGal4/+*.

Interaction of *foxo1* with *mnb* and *Hip1*

Hip1 and *Hip1*ΔANTH differentially affect eye development under conditions of *foxo1*-sensitized eye development

Expression of *mnb* has been shown to rescue the phenotype caused by over-expression of *foxo1* by *GMRGal4* (Rotchford 2006), which results in a decrease in ommatidia number, bristle number and ommatidia area (Kramer *et al.* 2003). To determine if *Hip1* interacts with *foxo1*, *GMR-Gal4* was used to direct the over-expression of murine *foxo1* plus other genes throughout the developing eye and ommatidia area, bristle number and ommatidia number were measured. Results are summarized in Table 4. Notably, directed expression of the truncated versions of *Hip1*, *Hip1*ΔANTH^{5.2} and *Hip1*ΔANTH^{11.2}, and *mnb* in the eye along with *foxo1*, have no effect upon the ommatidia area in males or females (Figures 19 and 20). In males only, flies in which *Hip1*^{L-2} and *Hip1*^{L-6} were over-expressed had significantly lower ommatidia area than controls (Figures 19 and 20). There is no difference with respect to ommatidia area between the two truncated versions of *Hip1*, but there is a difference in the full length versions of *Hip1* in males only (Figure 20).


For flies in which *Hip1*^{L-2}, *Hip1*^{L-6}, and *mnb* were over-expressed, there was a statistically significant decrease in bristle number compared to both *lacZ* and *GFP* controls (Figures 19 and 20). There is no difference in bristle number for the two truncated versions of *Hip1*, *Hip1*ΔANTH^{5.2} and *Hip1*ΔANTH^{11.2} compared to controls, with the exception of *Hip1*ΔANTH^{5.2}, which has increased bristle number compared to *lacZ* in females (Figure 19). There was no statistical difference between the two full length versions of *Hip1*, *Hip1*^{L-2} and *Hip1*^{L-6}, or between the two truncated versions of

Hip1, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{1.2}* in males and females in bristle number based on a one-way ANOVA.

Flies over-expressing all of the *Hip1* genes produced fewer ommatidia than the controls with the exception of *Hip1ΔANTH^{5.2}* females which show no difference compared to *lacZ* controls (Figures 19 and 20). As well, *mnb* females had significantly lower ommatidida number than the *GFP* control only (Figure 19). There was no statistical difference when examining ommatidia number between the two full length versions of *Hip1*, *Hip1^{L-2}* and *Hip1^{L-6}*, but there was a difference between the two truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{1.2}* (Figures 19 and 20).

There was no difference in the controls, *GFP* and *lacZ* for any condition observed (Figures 19 and 20). Electron micrographs of eyes demonstrate the differences in experimental genes compared to controls (Figures 19 and 20).


A



GFP



lacZ



mnbl



Hip1^{L-2}



Hip1^{L-6}



Hip1ΔANTH^{5.2}



Hip1ΔANTH^{11.2}

B







Figure 19. Biometric analysis of a potential role of *Hip1*, *Hip1*Δ*ANTH* and *mnb* in eye development along with the *GMRGal4* and *UASfoxo1* transgenes in females.

Directed expression of both full length versions of *Hip1*, *Hip1*^{L-2} and *Hip1*^{L-6}, the truncated versions of *Hip1*, *Hip1*Δ*ANTH*^{5.2} and *Hip1*Δ*ANTH*^{11.2}, and *mnb* effect eye development. Micrographs of eyes are shown in A. Graphic representations of ommatidia area, bristle number and ommatidia number are shown in B (values represent mean ± SEM). The genotypes are as follows: ***GFP*** *UASGFP*/*GMRGal4UASfoxo1*, ***lacZ*** *UASlacZ*/*GMRGal4UASfoxo1*, ***Hip1*^{L-2}** *UASHip1*^{L-2}/+; *GMRGal4UASfoxo1*/+, ***Hip1*^{L-6}** *UASHip1*^{L-6}/+; *GMRGal4UASfoxo1*/+, ***Hip1*Δ*ANTH*^{5.2}** *UASHip1*^{5.2}/*GMRGal4UASfoxo1*, ***Hip1*Δ*ANTH*^{11.2}** *UASHip1*^{11.2}/+; *GMRGal4UASfoxo1*/+, ***mnb*** *UASmnb*^{EY14320}/+; *GMRGal4UASfoxo1*/+. Bars with dissimilar superscripts indicate groups that differ significantly.

A



GFP



lacZ



mnb



Hip1^{L-2}



Hip1^{L-6}



Hip1 Δ ANTH^{5.2}



Hip1 Δ ANTH^{11.2}

B






Figure 20. Biometric analysis of a potential role of *Hip1*, *Hip1ΔANTH* and *mnb* on eye development along with the *GMRGal4* and *UASfoxo1* transgenes in males.

Directed expression of both full length versions of *Hip1*, *Hip1^{L-2}* and *Hip1^{L-6}*, the truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{11.2}*, and *mnb* effect eye development. Micrographs of eyes are shown in A. Graphic representations of ommatidia area (n=10), bristle number (n=10) and ommatidia number (n=10) are shown in B (values represent mean ± SEM). The genotypes are as follows: ***GFP*** *UASGFP/GMRGal4UASfoxo1*, ***lacZ*** *UASlacZ/GMRGal4UASfoxo1*, ***Hip1^{L-2}*** *UASHip1^{L-2}/+; GMRGal4UASfoxo1/+*, ***Hip1^{L-6}*** *UASHip1^{L-6}/+; GMRGal4UASfoxo1/+*, ***Hip1ΔANTH^{5.2}*** *UASHip1^{5.2}/GMRGal4UASfoxo1*, ***Hip1ΔANTH^{11.2}*** *UASHip1^{11.2}/+; GMRGal4UASfoxo1/+*, ***mnb*** *UASmn^{EY14320}/-; GMRGal4UASfoxo1/+*. Bars with dissimilar superscripts indicate groups that differ significantly.

Table 4. Comparison of differences in ommatidia area, bristle number and ommatidia number when *mn*b or *Hip1/Hip1ΔANTH* is expressed along with *foxo1* via the *GMRGal4* transgene.

Comparison	Sex	Ommatidia Area	Bristle Number	Ommatidia Number
<i>Hip1^{L-2}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>GFP</i>	M	↓ p < 0.001	↓ p < 0.0001	↓ p < 0.0001
<i>Hip1^{L-6}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>GFP</i>	M	NS	↓ p < 0.0001	↓ p < 0.0001
<i>Hip1ΔANTH^{5.2}</i>	F	NS	NS	↓ p < 0.0001
vs. <i>GFP</i>	M	NS	NS	↓ p < 0.0001
<i>Hip1ΔANTH^{11.2}</i>	F	NS	NS	↓ p < 0.01
vs. <i>GFP</i>	M	NS	NS	↓ p < 0.01
<i>mn</i> b	F	NS	↓ p < 0.0001	↓ p < 0.01
vs. <i>GFP</i>	M	NS	↓ p < 0.0001	NS
<i>Hip1^{L-2}</i>	F	NS	↓ p < 0.001	↓ p < 0.0001
vs. <i>lacZ</i>	M	NS	NS	↓ p < 0.0001
<i>Hip1^{L-6}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>lacZ</i>	M	↓ p < 0.0001	↓ p < 0.0001	↓ p < 0.0001
<i>Hip1ΔANTH^{5.2}</i>	F	NS	↑ p < 0.01	↓ p < 0.0001
vs. <i>lacZ</i>	M	NS	NS	↓ p < 0.0001
<i>Hip1ΔANTH^{11.2}</i>	F	NS	NS	NS
vs. <i>lacZ</i>	M	NS	NS	↓ p < 0.001
<i>mn</i> b	F	NS	↓ p < 0.001	NS
vs. <i>lacZ</i>	M	NS	NS	NS
<i>Hip1^{L-2}</i>	F	NS	NS	NS
vs. <i>Hip1^{L-6}</i>	M	↑ p < 0.0001	NS	NS
<i>Hip1ΔANTH^{5.2}</i>	F	NS	NS	↓ p < 0.01
vs. <i>Hip1ΔANTH^{11.2}</i>	M	NS	NS	↓ p < 0.01
<i>Hip1^{L-2}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{5.2}</i>	M	NS	↓ p < 0.01	↓ p < 0.0001
<i>Hip1^{L-6}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{5.2}</i>	M	↓ p < 0.0001	↓ p < 0.0001	↓ p < 0.0001
<i>Hip1^{L-2}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{11.2}</i>	M	NS	NS	↓ p < 0.0001
<i>Hip1^{L-6}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{11.2}</i>	M	↓ p < 0.0001	↓ p < 0.0001	↓ p < 0.0001
<i>Hip1^{L-2}</i>	F	NS	NS	↓ p < 0.0001
vs. <i>mn</i> b	M	NS	NS	↓ p < 0.0001
<i>Hip1^{L-6}</i>	F	NS	NS	↓ p < 0.0001
vs. <i>mn</i> b	M	p < 0.0001	NS	↓ p < 0.0001
<i>Hip1ΔANTH^{5.2}</i>	F	NS	↑ p < 0.0001	↓ p < 0.0001
vs. <i>mn</i> b	M	NS	NS	↓ p < 0.0001
<i>Hip1ΔANTH^{11.2}</i>	F	NS	↑ p < 0.0001	NS

vs. <i>mnb</i>	M	NS	NS	↓ p < 0.001
<i>GFP</i>	F	NS	NS	NS
vs. <i>lacZ</i>	M	NS	NS	NS

Arrows indicate increase (↑) or decrease (↓) in treatment.

p values based on Neuman-Keuls post-tests

F= female M= male

NS= not significant

Interaction of *mnb* and *Hip1* with each other

*The interaction between *mnb* and *Hip1* alters *foxo1* sensitized eye development when compared to *mnb* with *foxo1* and *Hip1* with *foxo1**

As *mnb* and *Hip1* have been found to interact with *foxo1* in the process of eye development and have been shown to interact biochemically, the interaction of *mnb* and *Hip1* with each other was investigated under the conditions of *foxo1*-sensitized eye development. To determine if *Hip1* and *mnb* interact, *GMR-Gal4* was used to direct the over-expression of murine *foxo1* plus other genes throughout the developing eye and ommatidia area, bristle number and ommatidia number were measured. A summary of these results can be seen in Table 5. Notably, when compared to *Hip1* with *foxo1* controls, *Hip1* and *mnb* together with *foxo1* increase ommatidia area for both full length versions, *Hip1*^{L-2} and *Hip1*^{L-6} and one truncated version of *Hip1*, *Hip1*ΔANTH^{1.2} (Figures 21 and 22). Compared to *mnb* and *foxo1* alone, *Hip1* and *mnb* together with *foxo1* increase ommatidia area for one full length version, *Hip1*^{L-2}, and one truncated version of *Hip1*, *Hip1*ΔANTH^{1.2} (Figures 21 and 22). Differences in ommatidia area were found when comparing the two full length versions of *Hip1* with *mnb* and the two truncated versions of *Hip1* with *mnb* (Figures 21 and 22).

Directed expression of *Hip1* with *mnb* and *foxo1* decreased bristle number for all versions of *Hip1* compared to the *Hip1* with *foxo1* controls (Figures 21 and 22). When compared to the *mnb* with *foxo1* control, both full length versions of *Hip1* were found to decrease the bristle number, whereas the truncated versions on *Hip1* increased the bristle number (Figures 21 and 22). In both males and females, there was no statistical difference when examining bristle number between the two full length versions of *Hip1*,

Hip1^{L-2} and *Hip1^{L-6}*, or in females expressing the truncated versions of *Hip1*, but there was a difference between the two truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{1.2}* in males (Figures 21 and 22).

There was no significant difference in ommatidia number between the full length versions of *Hip1* with *mnb* and *foxo1* compared to *Hip1* with *foxo1* controls. (Figures 21 and 22) Ommatidia number was increased in flies over-expressing the two truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{1.2}* compared to *Hip1* with *foxo1* controls (Figures 21 and 22). When compared to *mnb* with *foxo1* controls, both the full length versions and one truncated version of *Hip1* increased ommatidia number, while *Hip1ΔANTH^{1.2}* decreased ommatidia area (Figures 21 and 22). There was no difference between the two full length versions of *Hip1* with *mnb* and *foxo1*, but there was a difference between the two truncated versions in ommatidia area (Figures 21 and 22). Electron micrographs show the effects of expressing the two genes, *mnb* and *Hip1*, together (Figures 21 and 22). These results suggest that *mnb* and *Hip1* interact during *foxo1*-sensitized eye development to alter the ommatidia area, bristle number and ommatidia number compared to controls.

A

GMRGal4UAS foxo1 plus ...



mnb



Hip1^{L-2}



mnb; Hip1^{L-2}



Hip1^{L-6}



mnb; Hip1^{L-6}

A

GMRGal4UAS foxo1 plus ...



Hip1 Δ ANTH^{5.2}



mnb; Hip1 Δ ANTH^{5.2}



Hip1 Δ ANTH^{11.2}



mnb; Hip1 Δ ANTH^{11.2}

B






Figure 21. Biometric analysis of the interaction between *mnb* and *Hip1* during eye development along with the *GMRGal4* and *UASfoxo1* transgenes in females. Directed expression of both full length versions of *Hip1*, *Hip1^{L-2}* and *Hip1^{L-6}*, the truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{11.2}*, with *mnb* in the eye effect ommatidia area, bristle and ommatidia number. Micrographs of eyes are shown in A. Graphic representations of ommatidia area (n=10), bristle number (n=10) and ommatidia number (n=10) are shown in B (values represent mean ± SEM). The genotypes are as follows: *mnb UASmn^{EY14320}/+*; *GMRGal4UASfoxo1/+*, *Hip1^{L-2} UASHip1^{L-2}/+*; *GMRGal4UASfoxo1/+*, *mn^b; Hip1^{L-2} UASmn^{EY14320}/+*; *UASHip1^{L-2}/+*; *GMRGal4UASfoxo1/+*, *Hip1^{L-6} UASHip1^{L-6}/+*; *GMRGal4UASfoxo1/+*, *mn^b; Hip1^{L-6} UASmn^{EY14320}/+*; *UASHip1^{L-6}/+*; *GMRGal4UASfoxo1/+*, *Hip1ΔANTH^{5.2} UASHip1^{5.2}/GMRGal4UASfoxo1*, *mn^b; Hip1ΔANTH^{5.2} UASmn^{EY14320}/+*; *UASHip1^{5.2}/GMRGal4UASfoxo1*, *Hip1ΔANTH^{11.2} UASHip1^{11.2}/+*; *GMRGal4UASfoxo1/+*, *mn^b; Hip1ΔANTH^{11.2} UASmn^{EY14320}/+*; *UASHip1^{11.2}/+*; *GMRGal4UASfoxo1/+*. Bars with dissimilar superscripts indicate groups that differ significantly.

A

GMRGal4UAS foxo1 plus ...



mnb




Hip1^{L-2}



mnb; Hip1^{L-2}



Hip1^{L-6}



mnb; Hip1^{L-6}

A


GMRGal4UAS foxo1 plus ...




Hip1 Δ ANTH^{5.2}



mnb; Hip1 Δ ANTH^{5.2}



Hip1 Δ ANTH^{11.2}



mnb; Hip1 Δ ANTH^{11.2}

B




Figure 22. Biometric analysis of the interaction between *mnb* and *Hip1* during eye development along with the *GMRGal4* and *UASfoxo1* transgenes in males. Directed expression of both full length versions of *Hip1*, *Hip1^{L-2}* and *Hip1^{L-6}*, the truncated versions of *Hip1*, *Hip1ΔANTH^{5.2}* and *Hip1ΔANTH^{11.2}*, with *mnb* in the eye affect ommatidia area, bristle and ommatidia number. Micrographs of eyes are shown in A. Graphic representations of ommatidia area (n=10), bristle number (n=10) and ommatidia number (n=10) are shown in B (values represent mean ± SEM). The genotypes are as follows: *mnb UASmn^{EY14320}/+*; *GMRGal4UASfoxo1/+*, *Hip1^{L-2} UASHip1^{L-2}/+*; *GMRGal4UASfoxo1/+*, *mnb; Hip1^{L-2} UASmn^{EY14320}/+*; *UASHip1^{L-2}/+*; *GMRGal4UASfoxo1/+*, *Hip1^{L-6} UASHip1^{L-6}/+*; *GMRGal4UASfoxo1/+*, *mnb; Hip1^{L-6} UASmn^{EY14320}/+*; *UASHip1^{L-6}/+*; *GMRGal4UASfoxo1/+*, *Hip1ΔANTH^{5.2} UASHip1^{5.2}/GMRGal4UASfoxo1*, *mnb; Hip1ΔANTH^{5.2} UASmn^{EY14320}/+*; *UASHip1^{5.2}/GMRGal4UASfoxo1*, *Hip1ΔANTH^{11.2} UASHip1^{11.2}/+*; *GMRGal4UASfoxo1/+*, *mnb; Hip1ΔANTH^{11.2} UASmn^{EY14320}/+*; *UASHip1^{11.2}/+*; *GMRGal4UASfoxo1/+*. Bars with dissimilar superscripts indicate groups that differ significantly.

Table 5. Comparison of differences in ommatidia area, bristle number and ommatidia number when *mn*b and/or *Hip1*/*Hip1ΔANTH* is expressed along with *foxo1* via the *GMRGal4* transgene.

Comparison	Sex	Ommatidia Area	Bristle Number	Ommatidia Number
<i>mn</i> b; <i>Hip1</i> ^{L-2}	F	↑ p < 0.0001	↓ p < 0.0001	NS
vs. <i>Hip1</i> ^{L-2}	M	↑ p < 0.0001	↓ p < 0.001	NS
<i>mn</i> b; <i>Hip1</i> ^{L-6}	F	NS	↓ p < 0.01	NS
vs. <i>Hip1</i> ^{L-6}	M	↑ p < 0.0001	NS	NS
<i>mn</i> b; <i>Hip1ΔANTH</i> ^{5.2}	F	NS	↓ p < 0.001	NS
vs. <i>Hip1ΔANTH</i> ^{5.2}	M	NS	NS	↑ p < 0.001
<i>mn</i> b; <i>Hip1ΔANTH</i> ^{11.2}	F	↑ p < 0.001	↓ p < 0.01	↑ p < 0.001
vs. <i>Hip1ΔANTH</i> ^{11.2}	M	NS	NS	↑ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-2}	F	↑ p < 0.001	↓ p < 0.001	↓ p < 0.0001
vs. <i>mn</i> b	M	↑ p < 0.001	↓ p < 0.001	↓ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-6}	F	NS	↓ p < 0.01	↓ p < 0.0001
vs. <i>mn</i> b	M	NS	NS	↓ p < 0.0001
<i>mn</i> b; <i>Hip1ΔANTH</i> ^{5.2}	F	NS	↑ p < 0.01	↓ p < 0.01
vs. <i>mn</i> b	M	NS	↑ p < 0.01	↓ p < 0.001
<i>mn</i> b; <i>Hip1ΔANTH</i> ^{11.2}	F	↑ p < 0.01	↑ p < 0.01	↑ p < 0.0001
vs. <i>mn</i> b	M	NS	NS	↑ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-2}	F	↑ p < 0.01	NS	NS
vs. <i>mn</i> b; <i>Hip1</i> ^{L-6}	M	↑ p < 0.01	NS	NS
<i>mn</i> b; <i>Hip1ΔANTH</i> ^{5.2}	F	↓ p < 0.001	NS	↓ p < 0.0001
vs. <i>mn</i> b; <i>Hip1ΔANTH</i> ^{11.2}	M	NS	↑ p < 0.01	↓ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-2}	F	↑ p < 0.0001	↓ p < 0.0001	↓ p < 0.0001
vs. <i>mn</i> b; <i>Hip1ΔANTH</i> ^{5.2}	M	↑ p < 0.001	↓ p < 0.0001	↓ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-6}	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>mn</i> b; <i>Hip1ΔANTH</i> ^{5.2}	M	NS	↓ p < 0.0001	↓ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-2}	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>mn</i> b; <i>Hip1ΔANTH</i> ^{11.2}	M	↑ p < 0.01	↓ p < 0.001	↓ p < 0.0001
<i>mn</i> b; <i>Hip1</i> ^{L-6}	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>mn</i> b; <i>Hip1ΔANTH</i> ^{11.2}	M	NS	NS	↓ p < 0.0001
<i>mn</i> b	F	↑ p < 0.01	NS	↑ p < 0.0001
vs. <i>Hip1</i> ^{L-2}	M	NS	NS	↑ p < 0.0001
<i>mn</i> b	F	NS	NS	↑ p < 0.0001
vs. <i>Hip1</i> ^{L-6}	M	↑ p < 0.0001	NS	↑ p < 0.0001
<i>mn</i> b	F	NS	↓ p < 0.0001	↑ p < 0.01
vs. <i>Hip1ΔANTH</i> ^{5.2}	M	NS	↓ p < 0.01	↑ p < 0.0001
<i>mn</i> b	F	NS	↓ p < 0.0001	NS
vs. <i>Hip1ΔANTH</i> ^{11.2}	M	NS	NS	↑ p < 0.0001
<i>Hip1</i> ^{L-2}	F	N		

<i>Hip1^{l-2}</i>	F	N		
	F	NS		NS
vs. <i>Hip1^{l-6}</i>	M	↑ p < 0.0001	NS	NS
<i>Hip1ΔANTH^{5.2}</i>	F	NS	NS	↓ p < 0.01
vs. <i>Hip1ΔANTH^{l1.2}</i>	M	NS	NS	↓ p < 0.01
<i>Hip1^{l-2}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{5.2}</i>	M	NS	↓ p < 0.01	↓ p < 0.0001
<i>Hip1^{l-6}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{5.2}</i>	M	↓ p < 0.0001	↓ p < 0.0001	↓ p < 0.0001
<i>Hip1^{l-2}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001
vs. <i>Hip1ΔANTH^{l1.2}</i>	M	NS	NS	↓ p < 0.0001
<i>Hip1^{l-6}</i>	F	NS	↓ p < 0.0001	↓ p < 0.0001

Arrows indicate increase (↑) or decrease (↓) in treatment.

p values based on Neuman-Keuls post-tests

F= female

M= male

NS= not significant

Discussion

One of the goals of this research was to investigate the role of *mnb* in *Drosophila* neurogenesis by analysis of the microchaetae bristle formation on the dorsal notum. The original studies of *mnb* mutants have demonstrated a role for *mnb* during post-embryonic neurogenesis in *Drosophila* (Tejedor *et al.* 1995). However, since its discovery over a decade ago, few studies have been done on *mnb* in *Drosophila*. Mutant *mnb* flies with a reduction in gene expression show decreased volume of the optic lobes and central brain regions in adults and thus it was hypothesized that *mnb* may have a role in neurogenesis during the *development* of the dorsal notum. Recent study has indicated a novel role for *Hip1* during *Drosophila* neurogenesis, where the over-expression of *Hip1* affects the formation of microchaetae bristles (Moores *et al.* 2008). As a biochemical interaction was found between *mnb* and *Hip1* (Kang *et al.* 2005), it was imperative to determine if this interaction could be involved in the process of mechanosensory bristle formation on the dorsal notum. If *mnb* was found to play a role in bristle formation, this could be a source for the biological interaction between *mnb* and *Hip1*. No difference in the bristle density when *mnb* is expressed via either *apterousGal4* or *pannierGal4* was determined. This suggests that *mnb* is not the limiting factor in this process.

The insulin-receptor signalling pathway describes a well-studied mechanism whereby cell size, cell number and cell death are regulated (reviewed in Burgering 2008). Two components of this pathway, *akt* and *foxo1*, play opposite roles in this process, with *akt* promoting cell growth, and *foxo1* promoting cell death or cell cycle arrest. The dorsal notum has been used as a model to study the role of *Notch* (Romain *et al.* 2001) and has been exploited to show that *Hip1* plays a role in neurogenesis (Moores *et al.* 2008).

Although insulin signalling and neurogenesis have both been well-studied, research has not investigated the role of these two genes, *akt* and *foxo1*, in *Drosophila* neurogenesis. To study this potential novel role for insulin-receptor signalling components on mechanosensory bristle formation, *akt* and *foxo1* were ectopically expressed in the dorsal notum. Considering the important role that *akt* and *foxo1* play in the growth of cells, it is reasonable to think they would play a role in the development of mechanosensory bristle cells in the dorsal notum.

These experiments demonstrate that *akt* causes an increase in the bristle density under the direction of the *pannierGal4* transgene, to indicate a role for *akt* in bristle formation on the back in females. As *akt* plays a role in many developmental processes (Bhaskar and Hay 2007; Song and Wolfe 2007; Jiang and Lui 2008; Juntilla and Koretzky 2008; Tokunaga *et al.* 2008), it is reasonable to believe that *akt* may play a role in mechanosensory bristle formation. To the best of my knowledge this is the first time that a role for *akt* in neurogenesis on the *Drosophila* dorsal notum has been described. An increase in the level of *akt* is sufficient to shift the balance towards neurogenesis, which suggests that indeed the insulin signaling pathway is active in the formation of mechanosensory bristles on the dorsal notum.

When *foxo1* is expressed in the dorsal notum under the control of the *pannierGal4* transgene, there is no difference in bristle density compared to the controls, suggesting that *foxo1* does not interfere with neurogenesis. In contrast, over-expression of *foxo1* with *apterousGal4* leads to lethality. Further investigation of the ectopic expression of *foxo1* will be required to fully understand this finding.

During this study it was found that there is no statistical difference in any of the phenotypes studied for *GFP* and *lacZ*. The fact that there was no difference in these controls indicates that either of these genes can be used as controls in future experiments. As there is always a question on what controls to use when designing an experiment, this study brings useful knowledge to the scientific community as either of these controls will yield virtually the same results.

With minor exceptions, the two full length insertions of the *UASHip1* and two truncated versions of *UASHip1* transgenes do not give statistically different results from each other when over-expressed in the eye with *GMR* and with *GMR* and *foxo1*. This suggests that the two independently inserted transgenes do not have different activities. Examination of *Hip1*'s ability to influence *Drosophila* neurogenesis (Moore *et al.* 2008), and *Drosophila* eye development can certainly add to our understanding of this protein in the progression of HD.

Studies have suggested a role for *Hip1* as a pro-apoptotic protein, where over-expression of *Hip1* leads to caspase-dependent cell death (Hackam *et al.* 2000). *Hip1* over-expression with *GMR*, however, did not show any indication of cell death as bristle and ommatidia number were similar to controls. This suggests that although *Hip1* may act to increase apoptosis in cell culture, it does not play this role in live organisms.

The over-expression of *foxo1* in the developing eye leads to decreased ommatidia number, bristle number and ommatidia size (Kramer *et al.* 2003) presumably by altering aspects of the growth and cell survival signaling mechanisms. Ectopic *mnf* expression has been shown to interact with *foxo1* in the process of eye development through the suppression of the effects of *foxo1*, to result in ommatidia number, bristle number and

ommatidia size more similar to controls (Rotchford 2006). Under the sensitized growth conditions where the *GMRGal4* drives the *foxo1* transgene, both the full length versions and truncated versions of *Hip1* alter the growth of the eye compared to the controls. The full length versions of *Hip1* show decreased bristle number and decreased ommatidia number with no change in ommatidia size compared to the controls. The truncated versions of *Hip1* lacking the lipid-binding ANTH domain show normal ommatidia area, normal bristle number but decreased ommatidia number. These transgenes lead to significantly higher ommatidia number and bristle number than full length *Hip1* in the presence of *foxo1*. These findings show that the alternative versions of *Hip1* can play a slightly different role in eye development that is reminiscent of their dual role in *Drosophila* neurogenesis (Moores *et al.* 2008). Studies of *Hip1* in neurogenesis indicate that full length *Hip1* decreases microchaetae density and *Hip1* Δ ANTH increases microchaetae density (Moores *et al.* 2008). The presence or absence of the ANTH domain causes two very distinct phenotypes and suggests that *Hip1* may regulate eye development through a receptor-mediated endocytotic or vesicle trafficking mechanism, a mode similar to that hypothesized for *Hip1* in neurogenesis (Moores *et al.* 2008). Removal of the ANTH domain of *S. cerevisiae*'s Sla2P protein causes the protein to lose its endocytic ability (Sun *et al.* 2005), showing the importance of this domain in endocytosis. Like *Drosophila*, humans have multiple protein isoforms of *Hip1* (Curtis *et al.* 2005), so it is possible that this dual role of *Hip1* may occur in humans. This mechanism that employs two isoforms of the same protein to have opposing activities may be important in understanding the underlying mechanisms that contribute to HD.

This is the first account of a role for *Hip1* being described in *Drosophila* eye development.

The overexpression of *mnb* with *foxo1* shows decreased bristle number in males and females, and decreased ommatidia number in females. As it interacts with *foxo1*, it was hypothesized that *mnb* would increase cell growth by preventing *foxo1* activity. These results are inconsistent with the hypothesis and differ from previous results obtained for *mnb* (Rotchford 2006). It is unclear why results vary, but could be due to differences in experimental condition or sampling. There may very well be a delicate balance between the levels of *mnb* and *foxo1* and further research is needed to fully understand the role of *mnb* in insulin-receptor signaling and development.

Since both *mnb* and *Hip1* have been found to influence eye development under sensitized conditions, it is possible that these two genes may interact during this process. To investigate this, *Hip1* and *mnb* were ectopically expressed along with *foxo1* and *GMR* in the developing *Drosophila* eye. Compared to both *mnb* with *foxo1* and *Hip1* with *foxo1* as controls, *Hip1* with *mnb* and *foxo1* was found to increase ommatidia area, indicative of an increase in cell size. A previous biochemical interaction between *Hip1* and *mnb* resulted in the phosphorylation of *Hip1* by *mnb* and an increase in the growth of neurons (Kang *et al.* 2005). This study suggests that a similar role for *Hip1* and *mnb* may be happening in eye development to increase the growth of ommatidia. When compared to *Hip1* with *foxo1* controls, all versions of *Hip1* with *mnb* and *foxo1* were found to decrease the number of bristles formed. This suggests that *mnb* increases the ability of *Hip1* to decrease neurogenesis. Alternatively, when compared to *mnb* with *foxo1*, both full length versions of *Hip1* were found to decrease the bristle number, whereas the

truncated versions on *Hip1* increased the bristle number. This indicates that the two different versions of *Hip1* act differently with *mnb*, with the full length version decreasing neurogenesis and the truncated version increasing neurogenesis. This is reminiscent of the role that *Hip1* plays in *Drosophila* neurogenesis in the dorsal notum (Moore *et al.* 2008). Compared to the truncated versions of *Hip1* with *foxo1*, the truncated versions of *Hip1* with *mnb* and *foxo1* show a decrease in ommatidia number, with the full length *Hip1* having no effect. It is possible that *mnb* is influencing the truncated version only in the process of cell growth, but does not influence full length *Hip1* in this process. When compared to *mnb* with *foxo1* controls, both the full length versions and *Hip1* Δ *ANTH*^{5.2} increased ommatidia number, while *Hip1* Δ *ANTH*^{11.2} decreased ommatidia area. The two versions of *Hip1* may be influencing the activity of *mnb*, but appear to be doing so differentially.

It is clear that *mnb* and *Hip1* are interacting during the process of *foxo1*-sensitized eye development. As *mnb* has been shown to interact with *foxo1* and participate in the insulin signaling pathway, it could be that *Hip1* participates in this pathway as well. As little research has been done on *Hip1*, it is possible that participation in the insulin signaling pathway could be a novel role for *Hip1*. A second source for their interaction could be during receptor mediated endocytosis. It has been thought for the last two decades that *mnb* over-expression may alter receptor-mediated endocytosis (Wegiel *et al.* 2004). More specifically, *mnb* is thought to be involved in synaptic vesicle recycling and synaptic signal transmission by phosphorylating dynamin (Wegiel *et al.* 2004). *Hip1* has also been found to play a role in endocytosis, by binding to components of the endocytic apparatus, such as the adapter protein AP2, the heavy and light chains of the triskelia and

the lipid membrane via the ANTH domain (Metzler *et al.* 2001; Chen and Brodsky 2005). It is likely that Hip1 and mnv are interacting during receptor mediated endocytosis during the process of eye development.

Overall, this study has shown that *akt* and *foxo1* may play a role in bristle development in the dorsal notum, adding to the understanding of the insulin signaling pathway and its components. *Hip1* has a role in the process of *Drosophila* eye development, similar to the role found in *Drosophila* neurogenesis. During *foxo1*-sensitized eye development, mnv and Hip1 interact to influence cell size and cell number. *Drosophila* has proven to be a useful model to study these genes and how they interact in a living organism. In the future, *Drosophila melanogaster* will continue to be useful for studying the genes of diseases like Down syndrome and Huntington disease, a neurodegenerative disease and neurodegenerative disease in humans. As these are genes in two completely different diseases, finding how they interact could provide a key insight into finding therapies for neurodegenerative diseases.

References

- Abramoff, M. D., Magelhaes, P. J., and Ram, S. J. (2004). Image processing with Image J. *Biophotonics Int.* **11**, 36-42.
- Agrawai, N., Pallos, J., Slepko, N., Apostol, B., Bodai, L., Chang, L. W., Chiang, A. S., Thompson, L. M., and March, J. L. (2005). Identification of combinatorial drug regimens for treatment of Huntington's disease using *Drosophila*. *Proc. Natl. Acad. Sci. USA* **102**, 3777-3781.
- Ahn, K. J., Jeong, H. K., Choi, H. S., Ryoo, S. R., Kim, Y. J., Goo, J. S., Choi, S. Y., Han, J. S., Ha, I., and Song, W. J. (2006). Dyrk1A BAC transgenic mice show altered plasticity with learning and memory defects. *Neurobiol. Dis.* **22**, 463-472.
- Antonarakis, S. E. (2001). Chromosome 21: from sequence to applications. *Curr. Opin. Genet. Dev.* **11**, 241-246.
- Baker, N. E. (2001). Cell proliferation, survival, and death in the *Drosophila* eye. *Semin. Cell Dev. Biol.* **12**, 499-507.
- Bao, J., Sharp, A. H., Wankser, M. V., Becher, M., Schilling, G., Ross, C. A., Dawson, V. L., and Dawson, T. M. (1996). Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. *Proc. Natl. Acad. Sci. USA* **93**, 5037-5042.
- Becker, W., and Joost, H. G. (1999). Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. *Prog. Nucleic Acid Res. Mol. Biol.* **62**, 1-17.
- Bellen, H. J., Levis, R. W., Liao, G., He, Y., Carlson, J. W., Tsang, G., Evans-Holm, M., Hiesinger, P. R., Schulze, K. L., Rubin, G. M., Hoskins, R. A., Spradling, A. C. (2004). The BDGP gene disruption project: single transposon insertions associated with 40% of *Drosophila* genes. *Genetics* **167**, 761-781.
- Bescond, M., and Rahmani, Z. (2005). Dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A) interacts with the phytanoyl-CoA α -hydroxylase associated protein 1 (PAHX-AP1), a brain specific protein. *Int. J. Biochem. Cell Biol.* **37**, 775-783.
- Bhaskar, P. T., and Hay, N. (2007). The two TORCs and Akt. *Dev. Cell.* **12**, 487-502.
- Bier, E. (2005). *Drosophila*, the golden bug, emerges as a tool for human genetics. *Nature* **6**, 9-23.

- Bonini, N. M., and Fortini, M. E. (1999). Surviving *Drosophila* eye development: integrating cell death with differentiation during formation of a neural structure. *Bioessays* **21**, 991-1003.
- Branchi, I., Bicher, Z., Minghetti, L., Delabar, J. M., Malchiodi-Albedi, F., Gonzalez, M. C., Chettouh, Z., Nicolini, A., Chabert, C., Smith, D. J., Rubin, E. M., Migliore-Samour, D., and Alleva, E. (2004). Transgenic mouse in vivo library of human Down syndrome critical region 1: association between *DYRK1A* overexpression, brain development abnormalities, and cell cycle protein alteration. *J. Neuropathol. Exp. Neurol.* **63**, 429-440.
- Brand, A. H., Perrimon, N. (1994). Raf acts downstream of the EGF receptor to determine dorsoventral polarity during *Drosophila* oogenesis. *Genes Dev.* **8**, 629-639.
- Burgering, B. M. (2008). A brief introduction to FOXology. *Oncogene* **27**, 2258-2262.
- Burke, J. R., Enghild, J. J., Martin, M. E., Jou, Y. S., Myers, R. M., Roses, A. D., Vance, J. M., and Strittmatter, W. J. (1996). Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. *Nat. Med.* **2**, 347-350.
- Calleja, M., Moreno, E., Pelaz, S., and Morata, G. (1999). Visualization of gene expression in living adult *Drosophila*. *Science* **274**, 252-255.
- Chen, C. Y., and Brodsky, F. M. (2005). Huntingtin-interacting protein 1 (Hip1) and Hip1-related protein (Hip1R) bind the conserved sequence of clathrin light chains and thereby influence clathrin assembly *in vitro* and actin distribution *in vivo*. *J. Biol. Chem.* **280**, 6109-6117.
- Chen-Hwang, M. C., Chen, H. R., Elzinga, M., and Hwang, Y. W. (2002). Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate. *J. Biol. Chem.* **277**, 17597-17604.
- Coyle, J. T., Oster-Granite, M. L., and Gearhart, J. D. (1986). The neuobiologic consequences of Down syndrome. *Brain Res. Bull.* **16**, 773-787.
- Curtis, M. A., Penney, E. B., Pearson, J., Dragunow, M., Connor, B., and Faull, R. L. (2005). The disruption of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease brain. *Neuroscience* **132**, 777-778.
- de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Lüscher, B., and Becker, W. (2006). The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel *in vivo* phosphorylation site. *BMC Biochem.* **7**, 7-13.
- de Graaf, K., Hekerman, P., Spelten, O., Herrmann, A., Packman, L. C., Bussow, K., Muller-Newen, G., and Becker, W. (2004). Characterization of cyclin L2, a novel cyclin

with an arginine/serine-rich (RS) domain: phosphorylation by DYRK1A and colocalization with splicing factors. *J. Biol. Chem.* **279**, 4612-4624.

Delabar, J. M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J. L., Prieur, M., Noel, B., and Sinet, M. (1993). Molecular mapping of twenty-four features of Down syndrome on chromosome 21. *Eur. J. Hum. Genet.* **1**, 114-124.

Desai, U. A., Pallos, J., Ma, A. A. K., Stockwell, B. R., Thompson, L. M., Marsh, J. L., and Diamond, M. I. (2006). Biologically active molecules that reduce polyglutamine aggregation and toxicity. *Hum. Mol. Genet.* **15**, 2114-2124.

DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain. *Science* **277**, 1990-1993.

Engqvist-Goldstein, Å. Y., Warren, R. A., Kessels, M. M., Keen, J. H., Heuser, J., and Drubin, D. G. (2001). The actin-binding protein Hip1R associates with clathrin during early stages of endocytosis and promotes clathrin assembly *in vitro*. *J. Cell Biol.* **154**, 1209-1223.

Fotaki, V., Dierssen, M., Alcántara, S., Martínez, S., Martí, E., Casas, C., Visa, J., Soriano, E., Estivill, X., and Arbonés, M. L. (2002). Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. *Mol. Cell Biol.* **22**, 6636-6647.

Frankfort, B. J., and Mardon, G. (2002). R8 development in the *Drosophila* eye: a paradigm for neural selection and differentiation. *Development* **129**, 1295-1306.

Freeman M. (1996). Reiterative use of the EGF receptor triggers differentiation of all cell types in the *Drosophila* eye. *Cell* **87**, 651-660.

Gervais, F. G., Singaraja, R., Xanthoudakis, S., Gutekunst, C. A., Leavitt, B. R., Metzler, M., Hackam, A. S., Tam, J., Vaillancourt, J. P., Houtzager, V., Rasper, D. M., Roy, S., Hayden, M. R., and Nicholson, D. W. (2002). Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hip1. *Nat. Cell Biol.* **4**, 95-105.

Guimera, J., Casas, C., Estivill, X., and Pritchard, M. (1999). Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. *Genomics* **57**, 407-418.

Guimera, J., Casas, C., Pucharcos, C., Solans, A., Domenech, A., Planas, A. M., Ashley, J., Lovett, M., Estivill, X., and Pritchard, M. A. (1996). A human homologue of *Drosophila* minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. *Hum. Mol. Genet.* **5**, 1305-1310.

Gunawardena, S., Her, L. S., Brusch, R. G., Laymon, R. A., Niesman, I. R., Gordesky-Gold, B., Sintasath, L., Bonini, N. M., and Goldstein, L. S. (2003). Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in *Drosophila*. *Neuron* **40**, 25-40.

Gwack, Y., Sharma, S., Nardone, J., Tanasa, B., Iuga, A., Srianth, S., Okamura, H., Bolton, D., Feske, S., Hogan, P. G., and Rao, A. (2006). A genome-wide *Drosophila* RNAi screen identifies DYRK-family kinases as regulators of NFAT. *Nature* **441**, 646-650.

Hackam, A. S., Yassa, A. S., Singaraja, R., Metzler, M., Gutekunst, C. A., Gan, Lu., Warby, S., Wellington, C. L., Vaillancourt, J., Chen, N., Gervais, F. G., Raymond, L., Nicholson, D. W., and Hayden, M. R. (2000). Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. *J. Biol. Chem.* **275**, 41299-41308.

Hämmerle, B., Carnicero, C., Elizalde, J., Ceron, S., Martínez, S., and Tejedor, F. J. (2003). Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/Dyrk1A suggest a role in late neuronal differentiation. *Eur. J. Neurosci.* **17**, 2277-2286.

Hämmerle, B., Vera, E., Spreicher, S., Arencibia, R., Martínez, S., and Tejedor, F. J. (2002). Mnb/Dyrk1A is transiently expressed and asymmetrically segregated in neural progenitor cells at the transition to neurogenic divisions. *Dev. Biol.* **246**, 259-273.

Harper, P. S. (1992). The epidemiology of Huntington's disease. *Hum. Genet.* **89**, 365-376.

Hodgson, G., Agopvan, N., Smith, D., LePlane, F., McClutcheon, K., O'Kuskey, J. R., Bissada, N., Jamot, L., Roder, J., Rubin, E. M., and Hayden, M. R. (1999). YAC transgenic mice expressing mutant human Huntingtin show deficits in hippocampal long-term potentiation. *Neuron* **23**, 181-192.

Holtzman, D. A., Yang, S., and Drubin, D. G. (1993). Synthetic-lethal interactions identify two novel genes, SLA1 and SLA2, that control membrane cytoskeleton assembly in *Saccharomyces cerevisiae*. *J. Cell Biol.* **122**, 635-644.

Hyun, T. S., Rao, D. S., Saint-Dic, D., Michael, L. E., Kumar, P. D., Bradley, S. V., Mizukami, I. F., Oravec-Wilson, K. I., and Ross, T. S. (2004). HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. *J. Biol. Chem.* **279**, 14294-14306.

Jackson, G. R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P. W., MacDonald, M. E., and Zipursky, S. L. (1998). Polyglutamine-expanded human huntingtin transgenes induce degeneration of *Drosophila* photoreceptor neurons. *Neuron* **21**, 633-642.

Jacobs, P. A., Baikie, A. G., Court Brown, W. M., and Strong, J. A. (1959). The somatic chromosomes in mongolism. *Lancet* **I**, 10.

Jan, Y. N., and Jan, L. Y. (1994). Genetic control of cell fate specification in *Drosophila* peripheral nervous system. *Annu. Rev. Genet.* **28**, 373-393.

Jiang, B. H., and Liu, L. Z. (2008). AKT signaling in regulating angiogenesis. *Curr. Cancer Drug Targets* **8**, 19-26.

Juntilla, M. M., and Koretzky, G. A. (2008). Critical roles of the PI3K/Akt signaling pathway in T cell development. *Immunol. Lett.* **116**, 104-110.

Kalchman, M. A., Graham, R. K., Xia, G., Koide, H. B., Hodgson, J. G., Graham, K. C., Goldberg, Y. P., Gietz, R. D., Pickart, C. M., and Hayden, M. R. (1996). Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. *J. Biol. Chem.* **271**, 19385-19394.

Kalchman, M. A., Koide, H. B., McCutcheon, K., Graham, R. K., Nichol, K., Nishiyama, K., Lynn, F. C., Kazemi-Esfarjani, P., Wellington, C. L., Meltzer, M., Goldberg, Y. P., Kanazawa, I., Gietz, R. D., and Hayden, M. R. (1997). HIP1, a human homologue of *S. cerevisiae* Sla2p, interacts with membrane-associated huntingtin in the brain. *Nat. Genet.* **16**, 44-53.

Kang, J. E., Choi, S. A., Park, J. B., and Chung, K. C. (2005). Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells. *J. Neurosci. Res.* **81**, 62-72.

Kentrup, H., Becker, W., Heukelbach, J., Wilmes, A., Schurmann, A., Huppertz, C., Kainulainen, H., and Joost, H. G. (1996). Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. *J. Biol. Chem.* **271**, 3488-3495.

Kim, D., Won, J., Sin, D. W., Kang, J., Kim, Y., J., Choi, S. Y., Hwang, M. K., Jeong, B. W., Kim, G. S., Joe, C. O., Chung, S. H., and Song, W. J. (2004) Regulation of Dyrk1A kinase activity by 14-3-3. *Biochem. Biophys. Res. Commun.* **323**, 499-505.

Kinstrie, R., Lochhead, P. A., Sibbet, G., Morrice, N., and Cleghon, V. (2006). dDYRK2 and minibrain interact with the chromatin remodeling factors SNR1 and TRX. *Biochem. J.* **398**, 45-54.

Korenburg, J. R., Chen, X. N., Schipper, R., Sun, Z., Gonsky, R., Gerwehr, S., Carpenter, N., Daumer, C., Dgnan, P., and Distech, C. (1994). Down syndrome phenotypes: the consequences of chromosome imbalance. *Proc. Natl Acad. Sci. USA* **91**, 4997-5001.

Kramer, J. M., Davidge, J. T., Lockyer, J. M., and Staveley, B. E. (2003). Expression of *Drosophila* FOXO regulates growth and can phenocopy starvation. *BMC Dev Biol.* **3**, 5.

Kramer, J. M., and Staveley, B. E. (2003). GAL4 causes developmental defects and apoptosis when expressed in the developing eye of *Drosophila melanogaster*. *Genet. Mol. Res.* **2**, 43-47.

Laforet, G. A., Lee, H. S., Cadigan, B., Chang, P., Chase, K. O., Sapp, E., Martin, M., McIntyre, C., Williams, M., Reddy, P. H., Tagle, D., Stein, J. S., Boyce, F. M., DiFiglia, M., and Aronin, N. (1998). Development and characterization of a novel transgenic model of Huntington's disease which recapitulates features of the human illness. *Neurosci. Abstr.* **380**, 8.

Legendre-Guillemain, V., Metzler, M., Charbonneau, M., Gan, Lu, Chopra, V., Philie, J., Hayden, M. R., and McPherson, P. S. (2002). HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin. Identification of a novel interaction with clathrin light chain. *J. Biol. Chem.* **277**, 19897-19904.

Li, X. J., Li, S. H., Sharp, A. H., Nucifora Jr., F. C., Schilling, G., Lanahan, A., Worle, P., Snyder, S. H., and Ross, C. A. (1995). A huntingtin-associated protein enriched in brain with implications for pathology. *Nature* **378**, 398-402.

Lochhead, P. A., Sibbet, G., Kinstrie, R., Cleghon, T., Rylatt, M., Morrison, D. K., and Cleghon, V. (2003). dDYRK2: a novel dual-specificity tyrosine-phosphorylation-regulated kinase in *Drosophila*. *Biochem. J.* **374**, 381-391.

Mao, J., Maye, P., Kogerman, P., Tejedor, F. J., Toftgard, R., Xie, W., Wu, G., and Wu, D. (2002). Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1. *J. Biol. Chem.* **277**, 35156-35161.

Martí, E., Altafaj, X., Dierssen, M., de la Luna, S., Fotaki, V., Alvarez, M., Pérez-Riba, M., Ferrer, I., and Estivill, X. (2003). Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. *Brain Res.* **964**, 250-263.

Martínez de Lagrán, M., Altafaj, X., Gallego, X., Martí, E., Estivill, X., Sahún, I., Fillat, C., and Dierssen, M. (2004). Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. *Neurobiol Dis.* **15**, 132-142.

Matsuo, R., Ochiai, W., Nakashima, K., and Taga, T. (2001). A new expression cloning strategy for isolation of substrate-specific kinases by using phosphorylation site-specific antibody. *J. Immunol. Methods* **247**, 141-151.

Metzler, M., Legendre-Guillemain, V., Gan, Lu., Vikramjit, C., Kwok, A., McPherson, P. S., and Hayden, M. R. (2001). HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. *J. Biol. Chem.* **276**, 39271-39276.

Moore, J. N. (2006). Analysis of Huntingtin interacting protein 1 in *Drosophila melanogaster*. PhD thesis, Memorial University of Newfoundland.

- Moore, J.N., Roy, S., Nicholson, D. W., and Staveley, B. E. (2008). Huntingtin interacting protein 1 can regulate neurogenesis in *Drosophila*. *Eur. J. Neurosci.* **28**, 599-609.
- Morley, J. F., Brignull, H. R., Weyers, J. J., and Morimoto, R. I. (2002). The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. USA* **99**, 10417-10422.
- Okui, M., Ide, T., Morita, K., Funakoshi, E., Ito, F., Ogita, K., Yoneda, Y., Kudoh, J., and Shimizu, N. (1999). High-level expression of the *mnf/Dyrk1A* gene in brain and heart during early rat development. *Genomics* **62**, 165-171.
- Petersén, Å., Mani, K., and Brundin, P. (1999). Recent advances on the pathogenesis of Huntington's disease. *Exp. Neurol.* **157**, 1-18.
- Phelps, C. B., and Brand, A. H. (1998). Ectopic gene expression in *Drosophila* using GAL4 system. *Methods* **14**, 367-379.
- Qin, Z. H., Wang, Y., Sapp, E., Cuiffo, B., Wanker, E., Hayden, M. R., Kegel, K. B., Aronin, N., and DiFiglia, M. (2004). Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. *J. Neurosci.* **24**, 269-181.
- Raich, W. B., Moorman, C., Lacefield, C. O., Lehrer, J., Bartsch, D., Plasterk, R. H. A., Kandel, E. R., and Hobert, O. (2003). Characterization of *Caenorhabditis elegans* homologs of the Down syndrome candidate gene DYRK1A. *Genetics* **163**, 571-580.
- Ramain, P., Khechumian, K., Seugnet, L., Arbogast, N., Ackermann, C., and Heitzler, P. (2001). Novel Notch alleles reveal a Deltex-dependent pathway repressing neural fate. *Curr. Biol.* **11**, 1729-1738.
- Ranen, N. G., Stine, O. C., Abbott, M. H., Sher, M., Codori, A. M., Franz, M. L., Chao, N. I., Chung, A. S., Pleasant, N., Callahan, C., Kasch, L. M., Ghaffari, M., Chase, G. A., Kazazian, H., Brandt, J., Folstein, E., and Ross, C. A. (1995). Anticipation and instability of IT-15 (CAG)_N repeats in parent-offspring pairs with Huntington's disease. *Am. J. Hum. Genet.* **57**, 593-602.
- Rao, D. S., Bradley, S. V., Kumar, P. D., Hyun, T. S., Saint-Dic, D., Oravec-Wilson, K., Kleer, C. G., and Ross, T. (2003). Altered receptor trafficking in Huntingtin interacting protein 1-transformed cells. *Cancer Cell* **3**, 471-482.
- Romero, E., Cha, G. H., Verstreken, P., Ly, C. V., Hughes, R. E., Bellen, H. J., and Botas, J. (2008). Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. *Neuron* **57**, 27-40.

- Rotchford, J. L. E. (2006). An analysis of the interaction of *minibrain* mutants and insulin signaling pathway. Honours thesis, Memorial University of Newfoundland.
- Rubinsztein, D. C. (2002). Lessons from animal models of Huntington's disease. *Trends Genet.* **18**, 202-209.
- Rubinsztein, D. C., *et al.* (1997). Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. *Am. J. Hum. Genet.* **59**, 16-22.
- Sang, T. K., and Jackson, G. R. (2005). *Drosophila* models of neurodegenerative disease. *NeuroRx* **2**, 438-446.
- Sarkar, S., Krishna, G., Imarisio, S., Saiki, S., O'Kane, C. J., and Rubinsztein, D. C. (2008). A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. *Hum. Mol. Genet.* **17**, 170-178.
- Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates *in vitro* and *in vivo*. *Cell* **90**, 549-558.
- Sharp, A. H., and Ross, C. A. (1996). Neurobiology of Huntington's disease. *Neurobiol. Dis.* **3**, 3-15.
- Shindoh, N., Kudoh, J., Maeda, H., Yamaki, A., Minoshima, S., Shimizu, Y., and Shimizu, N. (1996). Cloning of a human homologue of the *Drosophila mnb/rat Dyrk* gene from "the Down syndrome critical region" of chromosome 21. *Biochem. Biophys. Res. Commun.* **225**, 92-99.
- Sitz, J H., Tigges, M., Baumgärtel, K., Khaspekov, L. G., and Lutz, B. (2004). Dyrk1A potentiates steroid hormone-induced transcription via chromatin remodeling factor Arip4. *Mol. Cell Biol.* **24**, 5821-5834.
- Skurat, A. V., and Dietrich, A. D. (2004). Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family protein kinases. *J. Biol. Chem.* **279**, 2490-2498.
- Smith, D. J., Stevens, M. E., Sudanagunta, S. P., Bronson, R. T., Makhinson, M., Watabe, A. M., O'Dell, T. J., Fung, J., Weier, H. U., Cheng, J. F., and Rubin, E. M. (1997). Functional screening of 2Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. *Nat. Genet.* **16**, 28-36.
- Smith, A., Ward, M. P., and Garrett, S. (1998). Yeast PKA represses Msn2p/Msn4p-dependent gene expression to regulate growth, stress response and glycogen accumulation. *EMBO J.* **17**, 3356-3564.

Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., MacDonald, M. E., Gusella, J. F., Harper, P. S., and Shaw, D. J. (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. *Nature Genet.* **4**, 393-397.

Song, D. F., and Wolfe, M. M. (2007). Glucose-dependent insulinotropic polypeptide and its role in obesity. *Curr. Opin. Endocrinol. Diabetes Obes.* **14**, 46-51.

Souza, G. M., Lu, S., and Kuspa, K. (1998). YakA, a protein kinase required for the transition from growth to development in Dictyostelium. *Development* **125**, 2291-2302.

Staveley, B. E., Ruel, L., Jin, J., Stambolic, V., Mastronardi, F. G., Heitzler, P., Woodgett, J. R., and Manoukian, A. S. (1998). Genetic analysis of protein kinase B (AKT) in Drosophila. *Curr. Biol.* **7**, 599-602.

Sun, Y., Kaksonen, M., Madden, D. T., Schekman, R., and Drubin, D. G. (2005). Interaction of Sla2p's ANTH domain with PtdIns(4,5)P₂ is important for actin-dependent endocytic internalization. *Mol. Biol. Cell* **16**, 717-730.

Tejedor, F., Zhu, X. R., Kaltenbach, E., Ackermann, A., Baumann, A., Canal, I., Heisenberg, M., Fischbach, K. F., and Pongs, O. (1995). minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila. *Neuron* **14**, 287-301.

Thomas, B. J., and Wassarman, D. A. (1999). A fly's eye view of biology. *Trends Genet.* **15**, 184-190.

Tokunaga, E., Oki, E., Egashira, A., Sadanaga, N., Morita, M., Kakeji, Y., and Maehara, Y. (2008). Deregulation of the Akt pathway in human cancer. *Curr. Cancer Drug Targets* **9**, 27-36.

Velier, J., Kim, M., Schwartz, C., Kim, T. W., Sapp, E., Chase, K., Aronin, N., and DiFiglia, M. (1998). Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. *Exp. Neurol.* **152**, 34-40.

Wanker, E. E., Rovira, C., Scherlinger, E., Hasenbank, R., Walter, S., Tait, D., Colicelli, J., and Lehrach, H. (1997). HIP1: a huntingtin interacting protein isolated by the yeast two-hybrid system. *Hum. Mol. Genet.* **6**, 487-495.

Wegiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Dowjat, K., Silverman, W. P., Reisberg, B., deLeon, M., Wisniewski, T., Adayev, T., Chen-Hwang, M. C., and Hwang, Y. W. (2004). Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. *Brain Res.* **1010**, 69-80.

Woods, Y. L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X., and Proud, C. G. (2001a). The kinase DYRK phosphorylates protein-synthesis initiation factor


EIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212, potential role for DYRK as a glycogen synthase kinase 3-priming kinase. *Biochem. J.* **355**, 609-615.

Woods, Y. L., Rena, G., Morrice, N., Barthel, A., Becker, W., Guo, S., Unterman, T. G., and Cohen, P. (2001b). The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser³²⁹ *in vitro*, a novel *in vivo* phosphorylation site. *Biochem. J.* **355**, 597-607.

Yang, E. J., Ahn, Y. S., and Chung, K. C. (2001). Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. *J. Biol. Chem.* **276**, 39819-39824.

Yeh, E., Gustafson, K., Boulianne, G. L. (1995). Green fluorescent protein as a vital marker and reporter of gene expression in Drosophila. *Proc. Natl. Acad. Sci. USA* **92**, 7036-7040.

Appendix 1



Schematic diagram for crosses made to eliminate the second chromosome balancer. *w;*

UASHip1^{L-2}/TM6B was generated in a and b shows *w; UAS Hip1^{L-6}/TM6B*.



